RespireRx Pharmaceuticals (RSPI) 10-Q 19 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 15, 2019
Document And Entity Information
Entity Registrant Name	RespireRx Pharmaceuticals Inc.
Entity Central Index Key	0000849636
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,045,073
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 94	$ 33,284
Advance payment on research contract	48,912	48,912
Prepaid expenses	57,737	38,880
Total current assets	106,743	121,076
Long-term prepaid insurance		3,114
Total assets	106,743	124,190
Current liabilities:
Accounts payable and accrued expenses, including $536,100 and $400,229 payable to related parties at September 30, 2019 and December 31, 2018, respectively	3,729,199	3,296,620
Accrued compensation and related expenses	1,890,334	1,304,434
Convertible notes payable including accrued interest of $95,425 and $62,635 at September 30, 2019 and December 31, 2018, respectively ($42,406 and $38,292, including accrued interest of $17,406 and $13,292, was deemed to be in default at September 30, 2019 and December 31, 2018, respectively and net of $104,858 and $27,969 of amortized debt discounts at September 30, 2019 and December 31, 2018, respectively (Note 4))	469,067	239,666
Note payable to SY Corporation (as defined below), including accrued interest of $351,189 and $315,307 at September 30, 2019 and December 31, 2018, respectively (payment obligation currently in default - Note 4)	723,187	744,441
Notes payable to officers, including accrued interest of $32,799 and $25,116 as of September 30, 2019 and December 31, 2018, respectively (Note 4)	140,649	109,216
Notes payable to former officer, including accrued interest of $38,091 and $26,561 as of September 30, 2019 and December 31, 2018, respectively (Note 4)	165,691	154,161
Other short-term notes payable	27,997	8,907
Total current liabilities	7,146,124	5,857,445
Commitments and contingencies (Note 8)
Stockholders' deficiency: (Note 6)
Series B convertible preferred stock, $0.001 par value; $0.6667 per share liquidation preference; aggregate liquidation preference $25,001; shares authorized: 37,500; shares issued and outstanding: 11; common shares issuable upon conversion at 0.00030 common shares per Series B share	21,703	21,703
Common stock, $0.001 par value; shares authorized: 65,000,000; shares issued and outstanding: 3,879,576 and 3,872,076 at September 30, 2019 and December 31, 2018, respectively	3,880	3,872
Additional paid-in capital	158,816,477	158,635,222
Accumulated deficit	(165,881,441)	(164,394,052)
Total stockholders' deficiency	(7,039,381)	(5,733,255)
Total liabilities and stockholders' deficiency	$ 106,743	$ 124,190

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Accounts payable and accrued expenses to related party	$ 536,100	$ 400,229
Accrued interest	17,406	13,292
Notes default amount	42,406	38,292
Debt discount	$ 104,858	$ 27,969
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	3,879,576	3,872,076
Common stock, shares outstanding	3,879,576	3,872,076
Officers [Member]
Accrued interest	$ 32,799	$ 25,116
Former Officers [Member]
Accrued interest	38,091	26,561
SY Corporation [Member]
Accrued interest	351,189	315,307
Convertible Notes Payable [Member]
Accrued interest	$ 95,425	$ 62,635
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation preference, per share	$ 0.6667	$ 0.6667
Preferred stock, liquidation preference value	$ 25,001	$ 25,001
Preferred stock, shares authorized	37,500	37,500
Preferred stock, shares issued	11	11
Preferred stock, shares outstanding	11	11
Preferred stock shares issuable upon conversion, per share	$ 0.00030	$ 0.00030

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating expenses:
General and administrative, including $121,600 and $204,383 to related parties for the three months ended September 30, 2019 and 2018, respectively, and $364,825 and $1,671,765 to related parties for the nine months ended September 30, 2019 and 2018, respectively	$ 279,930	$ 350,561	$ 874,834	$ 1,138,336
Research and development, including $122,400 to related parties for the three months ended September 30, 2019 and 2018, and $367,200 and $367,613 to related parties for the nine months ended September 30, 2019 and 2018, respectively	150,527	153,035	447,877	458,262
Total operating expenses	430,457	503,596	1,322,711	1,596,598
Loss from operations	(430,457)	(503,596)	(1,322,711)	(1,596,598)
Loss on extinguishment of debt and other liabilities in exchange for equity				(116,407)
Interest expense, including $2,589 and $11,714 to related parties for the three months ended September 30, 2019 and 2018, respectively, and $7,683 and $29,937 to related parties for the nine months ended September 30, 2019 and 2018, respectively	(70,168)	(35,161)	(221,813)	(96,230)
Foreign currency transaction gain (loss)	30,781	2,983	57,135	(108,582)
Net loss attributable to common stockholders	$ (469,844)	$ (535,774)	$ (1,487,389)	$ (1,917,817)
Net loss per common share - basic and diluted	$ (0.12)	$ (0.16)	$ (0.38)	$ (0.59)
Weighted average common shares outstanding - basic and diluted	3,874,465	3,398,940	3,873,097	3,228,528

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
General and administrative expense to related parties	$ 121,600	$ 204,383	$ 364,825	$ 1,671,765
Research and development expenses to related parties	122,400	122,400	367,200	367,613
Interest expense to related parties	$ 2,589	$ 11,714	$ 7,683	$ 29,937

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Series B Convertible Preferred Stock [Member]
Balance beginning	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703
Balance beginning, shares	37,500	37,500	37,500	37,500	37,500	37,500	37,500	37,500	37,500
Fair value of common stock warrants issued in connection with convertible notes
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes
Sale of common stock units in private placement, net of escrow fees of $5,000
Sale of common stock units in private placement, net of escrow fees of $5,000, shares
Issuance of common stock units in exchange for note payable to officer
Issuance of common stock units in exchange for note payable to officer, shares
Net loss
Balance ending	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703
Balance ending, shares	37,500	37,500	37,500	37,500	37,500	37,500	37,500	37,500	37,500
Common Stock [Member]
Balance beginning	$ 3,872	$ 3,872	$ 3,872	$ 3,350	$ 3,123	$ 3,065	$ 3,872	$ 3,065	$ 3,065
Balance beginning, shares	3,872,076	3,872,076	3,872,076	3,349,619	3,123,332	3,065,261	3,872,076	3,065,261	3,065,261
Common stock issued related to extinguishment of convertible notes					$ 227	$ 58
Common stock issued related to extinguishment of convertible notes, shares					226,287	58,071
Fair value of common stock warrants issued in connection with convertible notes
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes	$ 8
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes, shares	7,500
Sale of common stock units in private placement, net of escrow fees of $5,000				$ 190
Sale of common stock units in private placement, net of escrow fees of $5,000, shares				191,194
Issuance of common stock units in exchange for note payable to officer				$ 48
Issuance of common stock units in exchange for note payable to officer, shares				47,620
Net loss
Balance ending	$ 3,880	$ 3,872	$ 3,872	$ 3,588	$ 3,350	$ 3,123	$ 3,880	$ 3,588	$ 3,872
Balance ending, shares	3,879,576	3,872,076	3,872,076	3,588,433	3,349,619	3,123,332	3,879,576	3,588,433	3,872,076
Additional Paid-in Capital [Member]
Balance beginning	$ 158,768,984	$ 158,681,034	$ 158,635,222	$ 158,090,123	$ 157,546,861	$ 157,422,110	$ 158,635,222	$ 157,422,110	$ 157,422,110
Fair value of common stock options issued to consultants					335,303	14,474
Common stock issued related to extinguishment of convertible notes					207,959	110,277
Fair value of common stock warrants issued in connection with convertible notes		87,950	45,812
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes	47,493
Sale of common stock units in private placement, net of escrow fees of $5,000				195,558
Issuance of common stock units in exchange for note payable to officer				49,952
Net loss
Balance ending	158,816,477	158,768,984	158,681,034	158,335,633	158,090,123	157,546,861	158,816,477	158,335,633	158,635,222
Accumulated Deficit [Member]
Balance beginning	(165,411,597)	(164,934,384)	(164,394,052)	(163,184,304)	(162,548,941)	(161,802,262)	(164,394,052)	(161,802,262)	(161,802,262)
Fair value of common stock warrants issued in connection with convertible notes
Net loss	(469,844)	(477,213)	(540,332)	(535,774)	(635,363)	(746,679)
Balance ending	(165,881,441)	(165,411,597)	(164,934,384)	(163,720,078)	(163,184,304)	(162,548,941)	(165,881,441)	(163,720,078)	(164,394,052)
Balance beginning	(6,617,038)	(6,227,775)	(5,733,255)	(5,069,128)	(4,977,254)	(4,355,384)	(5,733,255)	(4,355,384)	(4,355,384)
Fair value of common stock options issued to consultants					335,303	14,474
Common stock issued related to extinguishment of convertible notes					208,186	110,335
Fair value of common stock warrants issued in connection with convertible notes		87,950	45,812
Fair value of common stock warrants and beneficial conversion feature associated with convertible notes	47,501
Sale of common stock units in private placement, net of escrow fees of $5,000				195,748
Issuance of common stock units in exchange for note payable to officer				50,000
Net loss	(469,844)	(477,213)	(540,332)	(535,774)	(635,363)	(746,679)	(1,487,389)	(1,917,817)	(2,591,790)
Balance ending	$ (7,039,381)	$ (6,617,038)	$ (6,227,775)	$ (5,359,154)	$ (5,069,128)	$ (4,977,254)	$ (7,039,381)	$ (5,359,154)	$ (5,733,255)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Deficiency (Parenthetical)	Sep. 30, 2018USD ($)
Statement of Stockholders' Equity [Abstract]
Escrow fees	$ 5,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (469,844)	$ (540,332)	$ (535,774)	$ (746,679)	$ (1,487,389)	$ (1,917,817)	$ (2,591,790)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discounts					119,793
Amortization of debt issuance costs					2,580
Loss on extinguishment of debt						105,253
Loss on extinguishment of other liabilities						11,154
Stock-based compensation and fees included in - General and administrative expenses						14,248
Foreign currency transaction (gain) loss	(30,781)		(2,983)		(57,135)	108,582
Changes in operating assets and liabilities:
Prepaid expenses					(15,743)	(13,030)
Accounts payable and accrued expenses					432,579	456,302
Accrued compensation and related expenses					585,900	836,849
Accrued interest payable					105,724	198,493
Net cash used in operating activities					(313,691)	(199,966)	(427,368)
Cash flows from financing activities:
Proceeds from sale of common stock units						200,750
Placement agent and other offering fees						(5,000)
Proceeds from convertible notes borrowings					263,501
Debt issuance costs					(8,000)
Proceeds from issuance of note payable to officer					25,000
Net cash provided by financing activities					280,501	195,750
Cash and cash equivalents:
Net decrease					(33,190)	(4,216)
Balance at beginning of period		$ 33,284		$ 84,902	33,284	84,902	84,902
Balance at end of period	$ 94		$ 80,686		94	80,686	$ 33,284
Cash paid for -
Interest					4,936	2,802
Non-cash financing activities:
10% convertible notes payable, including accrued interest of $62,267, exchanged for common stock						213,266
Accounts payable and accrued expenses extinguished with common stock options						335,529
Officer note payable, exchanged for common stock units						50,000
Issuance of common stock with 10% convertible notes					1,588
Warrants issued with convertible debt					80,698
Original issue discounts associated with convertible debt					$ 15,500

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Parenthetical)	9 Months Ended
	Sep. 30, 2018USD ($)
Statement of Cash Flows [Abstract]
Convertible notes payable percentage	10.00%
Accrued interest	$ 62,267

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Organization RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”) was formed in 1987 under the name Cortex Pharmaceuticals, Inc. to engage in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. On December 16, 2015, RespireRx filed a Certificate of Amendment to its Second Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to amend its Second Restated Certificate of Incorporation to change its name from Cortex Pharmaceuticals, Inc. to RespireRx Pharmaceuticals Inc. While previously developing potential applications for respiratory disorders, RespireRx has retained and expanded its ampakine intellectual property and data with respect to neurological and psychiatric disorders and is considering developing certain potential products in this platform, if it is able to obtain additional financing and/or strategic relationships. In August 2012, RespireRx acquired Pier Pharmaceuticals, Inc. (“Pier”), which is now its wholly-owned subsidiary. Basis of Presentation The condensed consolidated financial statements are of RespireRx and its wholly-owned subsidiary, Pier (collectively referred to herein as the “Company,” “we” or “our,” unless the context indicates otherwise). The condensed consolidated financial statements of the Company at September 30, 2019 and for the nine months and three months ended September 30, 2019 and 2018, are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the condensed consolidated financial position of the Company as of September 30, 2019 and the results of its condensed consolidated operations for the nine months and three months ended September 30, 2019 and 2018. Condensed consolidated operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2018 has been derived from the Company’s audited consolidated financial statements at such date. The condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the SEC.

Business

Business	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	2. Business The mission of the Company is to develop innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling. We are developing treatment options that address conditions that affect millions of people, but for which there are few or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”) and recovery from spinal cord injury (“SCI”), as well as certain neurological orphan diseases such as Fragile X Syndrome. RespireRx is developing a pipeline of new drug products based on our broad patent portfolios for two drug platforms: cannabinoids, including dronabinol (“∆9-THC”), and the ampakines, proprietary compounds that positively modulate AMPA-type glutamate receptors to promote neuronal function. RespireRx is developing a number of potential products. From the cannabinoid platform, two Phase 2 clinical trials have been completed demonstrating the ability of dronabinol to statistically significantly reduce the symptoms of OSA, which management believes is potentially a multi-billion-dollar market. Subject to raising sufficient financing (of which no assurance can be provided), we believe that we have put most of the necessary pieces into place to rapidly initiate a Phase 3 clinical trial program. By way of definition, when a new drug is allowed by the United States Food and Drug Administration (“FDA”) to be tested in humans, Phase 1 clinical trials are conducted in healthy people to determine safety and pharmacokinetics. If successful, Phase 2 clinical trials are conducted in patients to determine safety and preliminary efficacy. Phase 3 trials, large scale studies to determine efficacy and safety, are the final step prior to seeking FDA approval to market a drug. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, the Company has developed a family of novel, low impact ampakines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. From our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 efficacy trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression. CX717 has successfully completed a Phase 2 trial demonstrating the ability to statistically significantly reduce the symptoms of adult ADHD. In an early Phase 2 study, CX1739 improved breathing in patients with central sleep apnea. Preclinical studies have highlighted the potential ability of these ampakines to improve motor function in animals with spinal injury. Subject to raising sufficient financing (of which no assurance can be provided), we believe that we will be able to rapidly initiate a human Phase 2 study with CX1739 and/or CX717 in patients with spinal cord injury and a human Phase 2B study in patients with ADHD with either CX717 or CX1739. Going Concern The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred net losses of $1,487,389 and $469,844 for the nine months and three-months ended September 30, 2019, respectively and $2,591,790 for the fiscal year ended December 31, 2018, and negative operating cash flows of $313,692 for the nine months ended September 30, 2019 and $427,368 for the fiscal year ended December 31, 2018. The Company had only $94 of cash at September 30, 2019 and also had a stockholders’ deficiency of $7,039,381 at September 30, 2019 and expects to continue to incur net losses and negative operating cash flows for at least the next few years. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, and the Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, 2018, expressed substantial doubt about the Company’s ability to continue as a going concern. The Company is currently, and has for some time, been in significant financial distress. It has extremely limited cash resources and current assets and has no ongoing source of sustainable revenue. Fund raising efforts have been hampered by the Company’s low market capitalization and its common stock’s limited public float and low trading volume. Management is continuing to address various aspects of the Company’s operations and obligations, including, without limitation, debt obligations, financing requirements, intellectual property, licensing agreements, legal and patent matters and regulatory compliance, and has taken steps to continue to raise new debt and equity capital to fund the Company’s business activities from both related and unrelated parties. The Company is continuing its efforts to raise additional capital in order to be able to pay its liabilities and fund its business activities on a going forward basis, including the pursuit of the Company’s planned research and development activities. The Company regularly evaluates various measures to satisfy the Company’s liquidity needs, including strategic transactions, development and other agreements with collaborative partners such as Noramco Inc., and, when necessary, seeking to exchange or restructure the Company’s outstanding securities. The Company also is evaluating certain changes to its operations and structure to facilitate raising capital from sources that may be interested in financing only discrete aspects of the Company’s development programs. Such changes could include a significant reorganization, which may include the formation of one or more subsidiaries into which one or more programs may be contributed. To date, we have organized our two major platforms, cannabinoids and ampakines, into two operating divisions with the potential for evolving into stand-alone subsidiary companies. Towards this end, we have begun discussions focused on each of these platforms with potential investors and strategic partners. We also have begun interviewing individuals to assume executive management of the dronabinol platform. As a result of the Company’s current financial situation, the Company has experienced very limited access to external sources of debt and equity financing and the cost of such capital, both in terms of rates and other conditions, has been high. Accordingly, there can be no assurances that the Company will be able to secure additional financing in the amounts necessary to fully fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its operations entirely and liquidate.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates. Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high credit quality financial institutions. The Company’s research and development efforts and potential products rely on licenses from research institutions and if the Company loses access to these technologies or applications, its business could be substantially impaired. Cash Equivalents The Company considers all highly liquid short-term investments with maturities of less than three-months when acquired to be cash equivalents. Fair Value of Financial Instruments The authoritative guidance with respect to fair value of financial instruments established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, advances on research grants and accounts payable and accrued expenses) are considered by the Company to be representative of the respective fair values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd., formerly known as Samyang Optics Co. Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective fair values of such instruments due to the short-term nature of those instruments and their terms. Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants or a beneficial conversion feature, the convertible notes and warrants are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued at fair value in connection with and at the time of such financing. The value of debt discounts such as warrants, beneficial conversion features and original issue discounts are recorded as contra debt and amortized into interest expense over the life of the notes. Extinguishment of Debt The Company accounts for the extinguishment of debt in accordance with GAAP by comparing the carrying value of the debt to the fair value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs. Equipment Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, which range from three to five years. All equipment was fully depreciated as of September 30, 2019. Prepaid Insurance Long-term prepaid insurance represents the premium paid in March 2014 for directors’ and officers’ insurance tail coverage, which is being amortized on a straight-line basis over the policy period of six years. The amount amortizable in the ensuing twelve- month period is recorded as a current asset in the Company’s condensed consolidated balance sheet at each reporting date. As of September 30, 2019, all such prepaid amounts have been reclassified as current since the policy will expire within one year. Impairment of Long-Lived Assets The Company reviews its long-lived assets, including long-term prepaid insurance, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company has not deemed any long-lived assets as impaired at September 30, 2019. Stock-Based Awards The Company periodically issues common stock and stock options to officers, directors, outside consultants and vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers, directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated financial statements over the vesting period of the awards. The fair value of stock options granted as stock-based payments is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk- free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. There were no stock or stock option grants during the nine months ended September 30, 2019. For stock options requiring an assessment of value during the nine months ended September 30, 2018, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 2.56 % Expected dividend yield 0 % Expected volatility 185.41 % Expected life 4.5 The Company recognizes the fair value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option and warrant exercises. There were no stock options exercised during the nine months ended September 30, 2019 and 2018. Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of September 30, 2019, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of September 30, 2019, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations. Research and Development Research and development costs include compensation paid to management directing the Company’s research and development activities, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and product candidates. Research and development costs incurred by the Company under research grants are expensed as incurred over the life of the underlying contracts, unless the terms of the contract indicate that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. On May 6, 2016, the Company made an advance payment to Duke University with respect to the Phase 2A clinical trial of CX1739. At September 30, 2019, an asset balance of $48,912 remained from the advance payment. License Agreements Obligations incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate period, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Payments of such liabilities are made in the ordinary course of business. Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses. Earnings per Share The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At September 30, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. September 30, 2019 2018 Series B convertible preferred stock 11 11 Convertible notes payable 867,200 16,061 Common stock warrants 2,016,043 1,703,229 Common stock options 4,287,609 4,323,317 Total 7,170,863 5,507,312 Reclassifications Certain comparative figures in 2018 have been reclassified to conform to the current nine month and three month presentation. These reclassifications were immaterial, both individually and in the aggregate. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Notes Payable	4. Notes Payable Convertible Notes Payable On August 19, 2019, the Company issued a convertible note (the “August 2019 Convertible Note”) bearing interest at 10% per year. The maturity amount is $55,000 and it matures on the nine month anniversary, which is May 19, 2020. The Company incurred debt issuance costs of $2,500 for lender legal fees. The transaction included a $5,000 original issue discount, a warrant to purchase 150,000 shares of common stock and 7,500 Commitment Shares (as such term is defined in the definitive transaction documents), which were issued in connection with the August 2019 Convertible Note. The net proceeds to the Company was $47,500. Subject to certain limitations and adjustments as described in the August 2019 Convertible Note, the holder may convert the August 2019 Convertible Note at a fixed conversion price of $0.50 per share of common stock, provided that from the date that is six months after the issuance date, the conversion price shall be the lower of (a) $0.50 or (b) 60% multiplied by the lowest closing price of the common stock during the twenty (20) consecutive trading days prior to conversion. The Company evaluated all of the terms of the August 2019 Convertible Note and determined that, in accordance with ASC 815, there were no derivatives to be bifurcated or separately valued. However, there were five features of the August 2019 Convertible Note and the related securities purchase agreement that required valuation. They were: (i) the debt issuance costs of $2,500, (ii) the intrinsic value of the beneficial conversion feature, (iii) the value of the warrant, (iv) the original issue discount of $5,000, and (v) the value of the Commitment Shares. The Company amortizes each of these five on a straight-line basis over the life of the August 2019 Convertible Note. The Company valued the warrant using the Black-Scholes valuation method utilizing the following assumptions: (i) exercise price of $0.50, (ii) stock price of $0.65, (iii) life of five years, (iv) five-year risk free rate of 1.47% and (v) volatility of 175.5% that results in the value of one warrant of $0.623 and a total warrant value of $93,450. The amount to be recorded initially as the amount of the August 2019 Convertible Note was then calculated by determining the relative values as percentages of the net proceeds of the August 2019 Convertible Note ($47,500), the beneficial conversion feature ($16,500) and the warrant ($64.08% or $30,440) and the Commitment Shares (3.34% or $1,588). The debt issuance costs, original issue discount and the amount recorded as the intrinsic value of the beneficial conversion feature each are being amortized to interest expense on a straight-line basis over the life the August 2019 Convertible Note. The table below provides a summary of the August 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 55,000 Debt discounts, net of amortization of $8,504 (46,496 ) Accrued coupon interest 648 $ 9,152 On May 17, 2019, the Company issued a master convertible note (the “May 2019 Convertible Note”) issuable in tranches, bearing interest at 10% per year, bearing a maximum maturity amount of $150,000. The first tranche has a maturity amount of $50,000 and matures on the one year anniversary of the tranche which is May 17, 2020. There was a stated original issue discount of $5,000 and the Company incurred debt issuance costs of $2,000 for lender legal fees. Therefore, the net proceeds to the Company was $43,000. Subject to certain limitations and adjustments as described in the May 2019 Convertible Note, the holder may convert from the date of issuance to the maturity date, part or all of the May 2019 Convertible Note, inclusive of accrued interest, into the Company’s common stock at a variable conversion price that is the lesser of (i) lowest trading price as such term is defined in the May 2019 Convertible Note (the lowest closing bid price) in the twenty five day trading period prior to the date of the May 2019 Convertible Note (which price is now fixed at $0.25, the closing bid price on May 16, 2019), or (ii) the variable conversion price (as defined in the May 2019 Convertible Note) which is 61% of the market price (as defined in the May 2019 Convertible Note). The market price is the lowest trading price (closing bid) in the twenty five day trading day period up to the day prior to the conversion. If at any time while the Note is outstanding, the conversion price is equal to or lower than $0.35, then an additional eleven percent (11%) discount is to be factored into the conversion price until the May 2019 Convertible Note is no longer outstanding (resulting in a discount rate of 50% assuming no other adjustments are triggered). The lowest trading price on the date of inception of the May 2019 Convertible Note ($0.25) and the lowest market price were both below $0.35, the effective conversion rate on the inception date was $0.125. Therefore, on the inception date, the first tranche would have converted into 400,000 shares of the Company’s common stock. As of September 30, 2019, the first tranche would convert into 296,438 shares of common stock based upon a conversion price of $0.175 (50% of the lowest closing bid price during the applicable period). The Company evaluated all of the terms of the May 2019 Convertible Note and determined that, in accordance with Accounting Standard Codification (ASC) 815, there were no derivatives to be bifurcated or separately valued. However, there were four features of the May 2019 Convertible Note, the related securities purchase agreement and the warrant that was issued in connection therewith that required valuation. They were: (i) the original issue discount of $5,000, (ii) the debt issuance costs of $2,000, (iii) the beneficial conversion feature and (iv) the value of the warrant. The Company amortized (i) and (ii) above on a straight-line basis over the life of the tranche. The Company evaluated (iii) the intrinsic value of the beneficial conversion feature for a calculated value of $286,000 (($0.84 closing price minus $0.125 conversion price) x 400,000 shares). The Company calculated the warrant value using the Black-Scholes valuation method, utilizing the following assumptions: (a) exercise price of $1.18 per share, (b) stock price $0.84, (c) three year life (d) three year risk free rate of 2.15% and (e) volatility of 210.19% and determined that the value of one warrant was $0.774 and the total warrant value was $32,796 for the warrant exercisable into 42,373 shares of the Company’s common stock, par value $0.001. The amount to be recorded initially as the amount of the May 2019 Convertible Note was then calculated by determining the relative values as percentages of the maturity amount of the May 2019 Convertible Note ($50,000), the beneficial conversion feature ($286,000) and the warrant ($32,796). The respective percentages were 13.56%, 77.55 and 8.89%. The original issue discount, debt issuance costs, the intrinsic value of the beneficial conversion feature and proceeds allocated to the value of the warrant are being amortized to interest expense on a straight-line basis over the life the May 2019 Convertible Note. The table below provides a summary of the May 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 50,000 Debt discounts, net of amortization of $19,072 (31,149 ) Accrued coupon interest 1,876 $ 20,727 On April 24, 2019, the Company issued a convertible note (“the April 2019 Convertible Note”) bearing interest at 10% per year. The maturity amount is $58,500 and matures on the one year anniversary which is April 24, 2020. The Company incurred debt issuance costs of $3,500 for lender legal and due diligence fees. There was no stated original issue discount and no warrants were issued in connection with the April 2019 Convertible Note. The net proceeds to the Company was $50,000. Subject to certain limitations and adjustments as described in the April 2019 Convertible Note, the holder may, from the date that is one hundred eighty (180) days after the issuance to the maturity date, convert part or all of the April 2019 Convertible Note, inclusive of accrued interest, into the Company’s common stock at a variable conversion price that is 61% of the market price as defined in the April 2019 Convertible Note. The market price is the lowest trading price, which in turn is the lowest closing bid price in the twenty (20) trading days prior to conversion. The lowest closing bid price in the twenty (20) day period prior to inception was $0.65 which would calculate to a $0.3964 conversion price and further calculate to 147,541 conversion shares to be issued. The Company evaluated all of the terms of the April 2019 Convertible Note and determined that, in accordance with ASC 815, there were no derivatives to be bifurcated or separately valued. However, there were two features of the April 2019 Convertible Note and the related securities purchase agreement that required valuation. They were: (i) the debt issuance costs of $3,500, and (ii) the intrinsic value of the beneficial conversion feature. The Company amortized (i) on a straight-line basis over the life of the April 2019 Convertible Note. The Company evaluated (ii) as the closing price on the inception date minus the conversion price multiplied by the number of conversion shares and determined that the beneficial conversion feature had an intrinsic value of $44,950 (($0.701 closing price minus $0.3964 conversion price) x 147,541 shares). The debt issuance costs and the amount recorded as the intrinsic value of the beneficial conversion feature are each being amortized to interest expense on a straight-line basis over the life the April 2019 Convertible Note. The table below provides a summary of the April 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 58,500 Debt discounts, net of amortization of $21,238 (27,211 ) Accrued coupon interest 2,859 $ 34,148 On January 2, 2019, February 27, 2019, March 6, 2019 and March 14, 2019, the Company issued convertible notes (collectively, the “2019 Q1 Convertible Notes”) bearing interest at 10% per year. The 2019 Q1 Convertible Notes issued on January 2, 2019 matured on February 28, 2019 with a face amount of $10,000. The 2019 Q1 Convertible Notes issued on February 27, 2019, March 6, 2019 and March 14, 2019 matured on April 30, 2019 with an aggregate face amount of $100,000. Investors also received an aggregate of 110,000 common stock purchase warrants. The warrants were valued using the Black Scholes option pricing model calculated on the date of each grant and had an aggregate value of $78,780. Total value received by the investors was $188,780, the sum of the face value of the convertible note and the value of the warrant. Therefore, the Company recorded a debt discount associated with the warrant issuance of $45,812 and an initial value of the convertible notes of $64,188 using the relative fair value method. An additional $6,653 and $2,811 of interest expense was recorded based upon the 10% annual rate for the nine months and three months ended September 30, 2019, respectively. The 2019 Q1 Convertible Note that matured on February 28, 2019 was not paid and remains outstanding and continues to accrue interest. The 2019 Q1 Convertible Notes that matured on April 30, 2019 were not paid and remain outstanding and continue to accrue interest. Although the 2019 Q1 Convertible Notes are in default, the Company has not received any notices of default from any of the note holders. The 2019 Q1 Convertible Notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events other than the right, but not the obligation, for each investor to convert or exchange his or her 2019 Q1 Convertible Note, but not the warrant, into the next exempt private securities offering. The May 2019 Convertible Note and April 2019 Convertible Note, which the Company does not consider to have arisen from an offering, may be interpreted in such a way that the 2019 Q1 Convertible Note Holders have the right to convert or exchange. However, no holders of such notes have requested a conversion or exchange. The Company does not believe that an offering occurred as of September 30, 2019 or as of the date of the issuance of these financial statements. Therefore, the number of shares of common stock (or preferred stock) into which the 2019 Q1 Convertible Notes may convert is not determinable and the Company has not accounted for any additional consideration. The warrants to purchase 110,000 shares of common stock issued in connection with the sale of the 2019 Q1 Convertible Notes are exercisable at a fixed price of $1.50 per share of common stock, provide no right to receive a cash payment, and included no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded derivatives to be identified, bifurcated and valued in connection with this financing. During December 2018, convertible notes (“2018 Convertible Notes”) bearing interest at 10% per year and maturing on February 28, 2019 and warrants were sold to investors with an aggregate face amount of $80,000. Investors also received 80,000 common stock purchase warrants. The warrants were valued using the Black Scholes option pricing model calculated on the date of each grant and had an aggregate value of $68,025. Total value received by the investors was $148,025, the sum of the face value of the convertible note and the value of the warrant. Therefore, the Company recorded a debt discount associated with the issuance of the warrants of $36,347 and an initial value of the convertible notes of $43,653 using the relative fair value method. An additional $6,067 and $2,044 of interest expense was recorded based upon the 10% annual rate for the nine months and three months ended September 30, 2019, respectively. The 2018 Convertible Notes matured on February 28, 2019, were not paid, remain outstanding and continue to accrue interest. Although the 2018 Convertible Notes are in default, the Company has not received any notices of default from any of the note holders. The 2018 Convertible Notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events other than the right, but not the obligation for each investor to convert or exchange his or her 2018 Convertible Note, but not the warrant, into the next exempt private securities offering. The May 2019 Convertible Note and April 2019 Convertible Note, which the Company does not consider to have arisen from an offering, may be interpreted in such a way that the 2019 Q1 Convertible Note Holders have the right to convert or exchange. However, no holders of such notes have requested a conversion or exchange. The Company does not believe that an offering occurred as of September 30, 2019 or as of the date of the issuance of these financial statements. Therefore, the number of shares of common stock (or preferred stock) into which the 2018 Convertible Notes may convert is not determinable and the Company has not accounted for any additional consideration. The warrants to purchase 80,000 shares of common stock issued in connection with the sale of the 2018 Convertible Notes are exercisable at a fixed price of $1.50 per share of common stock, provide no right to receive a cash payment, and included no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded derivatives to be identified, bifurcated and valued in connection with this financing. The 2018 Convertible Notes and 2019 Q1 Convertible Notes consist of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of notes payable $ 190,000 $ 80,000 Discount associated with issuance of warrants net of amortization of $82,159 as of September 30, 2019 and $8,379 as of December 31,2018 - (27,968 ) Accrued interest payable 13,121 401 $ 203,121 $ 52,433 Convertible notes were also sold to investors in 2014 and 2015 (“Original Convertible Notes), which aggregated a total of $579,500, had a fixed interest rate of 10% per annum and those that remain outstanding are convertible into common stock at a fixed price of $11.3750 per share. The Original Convertible Notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events. The warrants to purchase 50,945 shares of common stock issued in connection with the sale of the convertible notes were exercisable at a fixed price of $11.3750 per share. All such warrants have either been exchanged as part of April and May 2016 note and warrant exchange agreements or expired on September 15, 2016. The maturity date of the Original Convertible Notes was extended to September 15, 2016 and included the issuance of 27,936 additional warrants to purchase common stock, exercisable at $11.375 per share of common stock, which expired on September 15, 2016. The remaining outstanding Original Convertible Notes (including those for which default notices have been received) consist of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of notes payable $ 125,000 $ 125,000 Accrued interest payable 76,920 62,233 $ 201,920 $ 187,233 As of September 30, 2019, principal and accrued interest on the one remaining outstanding Original Convertible Note, which is subject to a default notice and which therefore accrues annual interest at 12% instead of 10%, totaled $42,406, of which $17,406 was accrued interest. As of December 31, 2018, principal and accrued interest on convertible notes subject to default notices totaled $38,292 of which $13,292 was accrued interest. As of September 30, 2019 all of the outstanding Original Convertible Notes, inclusive of accrued interest, were convertible into an aggregate of 17,810 shares of the Company’s common stock, including 6,765 shares attributable to accrued interest of $76,920 payable as of such date. As of December 31, 2018, the outstanding Original Convertible Notes were convertible into 16,460 shares of the Company’s common stock, including 5,471 shares attributable to accrued interest of $62,233 payable as of such date. Such Original Convertible Notes will continue to accrue interest until exchanged, paid or otherwise discharged. There can be no assurance that any of the additional holders of the remaining Original Convertible Notes will exchange their notes. Note Payable to SY Corporation Co., Ltd. On June 25, 2012, the Company borrowed 465,000,000 Won (the currency of South Korea, equivalent to approximately $400,000 United States Dollars as of that date) from and executed a secured note payable to SY Corporation, an approximately 20% common stockholder of the Company at that time. SY Corporation was a significant stockholder and a related party at the time of the transaction but has not been a significant stockholder or related party of the Company subsequent to December 31, 2014. The note accrues simple interest at the rate of 12% per annum and had a maturity date of June 25, 2013. The Company has not made any payments on the promissory note. At June 30, 2013 and subsequently, the promissory note was outstanding and in default, although SY Corporation has not issued a notice of default or a demand for repayment. Management believes that SY Corporation is in default of its obligations under its January 2012 license agreement, as amended, with the Company, but the Company has not yet issued a notice of default. The Company has in the past made several efforts towards a comprehensive resolution of the aforementioned matters involving SY Corporation. During the nine months ended September 30, 2019, there were no communications between the Company and SY Corporation. The promissory note is secured by collateral that represents a lien on certain patents owned by the Company, including composition of matter patents for certain of the Company’s high impact ampakine compounds and the low impact ampakine compounds CX2007 and CX2076, and other related compounds. The security interest does not extend to the Company’s patents for its ampakine compounds CX1739 and CX1942, or to the patent for the use of ampakine compounds for the treatment of respiratory depression. Note payable to SY Corporation consists of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 351,188 315,307 Foreign currency transaction adjustment (27,775 ) 29,360 $ 723,187 $ 744,441 Interest expense with respect to this promissory note was $35,881 and $12,092 for the nine months and three months ended September 30, 2019, and for the nine months and three months ended September 30, 2018, respectively. Notes Payable to Officers and Former Officers For the nine months and three months ended September 30, 2019, $7,683 and $2,589 respectively was charged to interest expense with respect to notes payable to Dr. Arnold S. Lippa, an officer of the Company. For the nine months and three months ended September 30, 2018, $9,517 and $3,319 respectively was charged to interest expense with respect to notes payable to Dr. Arnold S. Lippa. For the nine months and three months ended September 30, 2019, $11,530 and $3,886 respectively was charged to interest expense with respect notes payable to to Dr.James S. Manuso, a former officer of the Company. For the nine months and three months ended September 30, 2018 $9,754 and $3,564 respectivley was charged to interest expense with respect to notes payable to Dr. James S. Manuso. As of September 30, 2018, Dr. James S. Manuso resigned as executive officer in all capacities and as a member of the Board of Directors of the Company. All of the $11,530 of interest expense noted above for the nine months ended September 30, 2019, was incurred while Dr. Manuso was no longer an officer. Other Short-Term Notes Payable Other short-term notes payable at September 30, 2019 and December 31, 2018 consisted of premium financing agreements with respect to various insurance policies. At the inception of the new policy in March 2019, a premium financing agreement was payable in the initial amount of $61,746, with interest at 9% per annum, in nine monthly installments of $7,120. At September 30, 2019 and December 31, 2018, the aggregate amount of the short-term notes payable was $27,997 and $8,907 respectively.

Settlement and Payment Agreemen

Settlement and Payment Agreements	9 Months Ended
	Sep. 30, 2019
Settlement And Payment Agreements
Settlement and Payment Agreements	5. Settlement and Payment Agreements On August 21, 2019, the Company entered into a Settlement Agreement and Release with Salamandra, LLC (“Salamandra”) in respect to amounts owed to Salamandra, which totaled $202,395 as of September 30, 2019. The settlement agreement reduces the amount owed to a lump-sum payment of $125,000 payable by November 30, 2019, if by that date, the Company has raised an aggregate of at least $600,000 in working capital. Should the Company raise less than $600,000, the Company may pay 21% of the amount raised and cancel that portion of the debt. If the Company is unable to raise $600,000 by November 30, 2019, the settlement agreement becomes null and void. Upon receipt of the settlement payment, mutual releases will become effective with respect to the remaining amount of debt on that date. On October 22, 2019 and November 4, 2019, the Company raised an aggregate of $202,400 in working capital from the net proceeds of the October 2019 Convertible Note and the November 2019 Convertible Note (see Note 9. Subsequent Events). Total working capital raised by the Company from the inception of the Settlement Agreement through November 4, 2019 was $202,400. On September 23, 2019, the Company and a vendor agreed in principle to a proposed settlement agreement, which has not been documented in the form of a formal agreement. The agreement in principal calls for no reduction in the overall amount to be paid by the Company, which amount is not in dispute, but addresses only a payment schedule. The agreement in principal calls for a payment of a minimum of $100,000 on or before November 30, 2019 assuming the Company has raised at least $600,000 by that date and thereafter calls for a payment of $50,000 per month until paid in full. If the Company does not make a scheduled payment, the agreement in principal would be deemed null and void.

Stockholders' Deficiency

Stockholders' Deficiency	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Deficiency	6. Stockholders’ Deficiency Preferred Stock The Company has authorized a total of 5,000,000 shares of preferred stock, par value $0.001 per share. As of September 30, 2019 and December 31, 2018, 1,250,000 shares were designated as 9% Cumulative Convertible Preferred Stock (non-voting, “9% Preferred Stock”); 37,500 shares were designated as Series B Convertible Preferred Stock (non-voting, “Series B Preferred Stock”); 205,000 shares were designated as Series A Junior Participating Preferred Stock (non-voting, “Series A Junior Participating Preferred Stock”); and 1,700 shares were designated as Series G 1.5% Convertible Preferred Stock. Accordingly, as of September 30, 2019 and December 31, 2018, 3,505,800 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate. Series B Preferred Stock outstanding as of September 30, 2019 and 2018 consisted of 37,500 shares issued in a May 1991 private placement. Each share of Series B Preferred Stock is convertible into approximately 0.00030 shares of common stock at an effective conversion price of $2,208.375 per share of common stock, which is subject to adjustment under certain circumstances. As of September 30, 2019 and December 31, 2018, the shares of Series B Preferred Stock outstanding are convertible into 11 shares of common stock. The Company may redeem the Series B Preferred Stock for $25,001, equivalent to $0.6667 per share, an amount equal to its liquidation preference, at any time upon 30 days prior notice. Common Stock There are 3,879,576 shares of the Company’s common stock outstanding as of September 30, 2019. The Company has reserved an aggregate of 7,401,292 for conversions of convertible debt which reserve includes contractual reserves totaling 7,383,482 shares of the Company’s common stock, which exceeds the actual conversion amounts under those contracts as of September 30, 2019 by 6,534,657 shares. In addition, The Company has reserved 6,303,652 shares of the Company’s common stock for exercises of common stock purchase options granted and warrants issued. There are 6,497 shares of the Company’s common stock reserved as Pier contingent shares. There are 4,490,578 shares reserved for future issuances under the Company’s 2014 and 2015 Plans (as hereafter defined). There are 43,452,954 shares of the Company’s common stock available for future issuances. Common Stock Warrants Information with respect to the issuance and exercise of common stock purchase warrants in connection with the Convertible Note Payable and the related warrant, and Notes Payable to Officers, is provided at Note 4. A summary of warrant activity for the nine months ended September 30, 2019 is presented below. Weighted Average Weighted Remaining Number of Average Contractual Shares Exercise Price Life (in Years) Warrants outstanding and exerciable at December 31, 2018 1,783,229 $ 2.20393 3.06 Issued 302,372 0.95908 Expired (69,558 ) 2.65928 Warrants outstanding and exercisable at September 30, 2019 2,016,043 $ 1.99011 2.73 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2019: Exercise Price Warrants (Shares) Warrants (Shares) Expiration Date $ 0.5000 150,000 150,000 August 19, 2024 $ 1.0000 916,217 916,217 September 20, 2022 $ 1.1800 42,372 42,372 May 17, 2022 $ 1.5000 190,000 190,000 December 30, 2023 $ 1.5620 130,284 130,284 December 31, 2021 $ 1.5750 238,814 238,814 April 30, 2023 $ 2.7500 8,000 8,000 September 20, 2022 $ 4.8750 108,594 108,594 September 30, 2020 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 2,016,043 2,016,043 Based on a fair market value of $0.45 per share on September 30, 2019, the intrinsic value of exercisable in-the-money common stock warrants as of September 30, 2019 was $7,500. A summary of warrant activity for the nine months ended September 30, 2018 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding and exercisable at December 31, 2017 1,464,415 $ 2.68146 3.73 Issued 238,814 1.57500 Warrants outstanding and exercisable at September 30, 2018 1,703,229 $ 2.52632 4.08 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2018: Exercise Price Warrants Outstanding Warrants Exercisable Expiration Date $ 1.0000 916,217 916,217 September 20, 2022 $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 130,284 130,284 December 31, 2021 $ 1,5750 238,814 238,814 April 30, 2023 $ 2.7500 8,000 8000 September 20, 2022 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 1,703,229 1,703,229 Based on a fair market value of $0.7171 per share on September 30, 2018, there were no exercisable in-the money common stock warrants as of September 30, 2018. Stock Options On March 18, 2014, the stockholders of the Company holding a majority of the votes to be cast on the issue approved the adoption of the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “2014 Plan”), which had been previously adopted by the Board of Directors of the Company, subject to stockholder approval. The Plan permits the grant of options and restricted stock with respect to up to 325,025 shares of common stock, in addition to stock appreciation rights and phantom stock, to directors, officers, employees, consultants and other service providers of the Company. On June 30, 2015, the Board of Directors adopted the 2015 Stock and Stock Option Plan (the “2015 Plan”). The 2015 Plan initially provided for, among other things, the issuance of either or any combination of restricted shares of common stock and non- qualified stock options to purchase up to 461,538 shares of the Company’s common stock for periods up to ten years to management, members of the Board of Directors, consultants and advisors. The Company has not and does not intend to present the 2015 Plan to stockholders for approval. On August 18, 2015, the Board of Directors increased the number of shares that may be issued under the 2015 Plan to 769,231 shares of the Company’s common stock. On March 31, 2016, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 1,538,461 shares of the Company’s common stock. On January 17, 2017, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 3,038,461 shares of the Company’s common stock. On December 9, 2017, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 6,985,260 shares of the Company’s common stock. On December 28, 2018, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 8,985,260 shares of the Company’s common stock. Information with respect to the Black-Scholes variables used in connection with the evaluation of the fair value of stock- based compensation is provided at Note 3. There were no grants of common stock options or of stock for the nine month period ended September 30, 2019. A summary of stock option activity for the nine months ended September 30, 2019 is presented below. Number of Weighted Weighted Options outstanding and exercisable at December 31, 2018 4,344,994 $ 3.7634 7.38 Expired (57,385 ) (15.6139 ) Options outstanding and exercisable at September 30, 2019 4,287,609 $ 3.3798 5.23 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2019: Exercise Price Options Outstanding Options Exercisable Expiration Date $ 0.7000 21,677 21,677 November 21, 2023 $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,287,609 4,287,609 There was no deferred compensation expense for the outstanding stock options at September 30, 2019. Based on a fair market value of $0.45 per share on September 30, 2019, there was no intrinsic value of exercisable in-the-money common stock options as of September 30, 2019. A summary of stock option activity for the nine months ended September 30, 2018 is presented below. Number of Weighted Weighted Options outstanding and exercisable at December 31, 2017 3,996,167 $ 3.7634 6.30 Granted 327,150 1.1267 4.50 Options outstanding and exercisable at September 30, 2018 4,323,317 $ 3.5855 6.17 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2018: Exercise Price Options Outstanding Options Exercisable Expiration Date $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,323,317 4,323,317 Based on a fair market value of $0.7101 per share on September 30, 2018, there were no exercisable in-the-money common stock options as of September 30, 2018. Reserved and Unreserved Shares of Common Stock On January 17, 2017, the Board of Directors of the Company approved the adoption of an amendment of the Amended and Restated RespireRx Pharmaceuticals, Inc. 2015 Stock and Stock Option Plan (as amended, the “2015 Plan”). That amendment increases the shares issuable under the plan by 1,500,000, from 1,538,461 to 3,038,461. On December 9, 2017, the Board of Directors further amended the 2015 Plan to increase the number of shares that may be issued under the 2015 Plan to 6,985,260 shares of the Company’s common stock. On December 28, 2018, the Board of Directors further amended the 2015 Plan to increase the number of shares that may be issued under the 2015 Plan to 8,985,260 shares of the Company’s common stock. Other than the change in the number of shares available under the 2015 Plan, no other changes were made to the 2015 Plan by these amendments noted above. At September 30, 2019, the Company had 65,000,000 shares of common stock authorized and 3,879,576 shares of common stock issued and outstanding. The Company has reserved 11 shares of common stock for the conversion of the Series B Preferred Stock. The Company has reserved an aggregate of 7,401,292 for conversions of convertible debt which reserve includes contractual reserves totaling 7,383,482 shares of the Company’s common stock, which exceeds the actual conversion amounts under those contracts as of September 30, 2019 by 6,516,847 shares. In addition, The Company has reserved 6,303,652 shares of the Company’s common stock for exercises of common stock purchase options granted and warrants issued. There are 6,497 shares of the Company’s common stock reserved as Pier contingent shares. There are 4,490,578 shares reserved for future issuances under the Company’s 2014 and 2015 Plans (as hereafter defined). Accordingly, after taking into consideration the reserved shares, there are 42,918,394 shares of the Company’s common stock available for future issuances. The Company expects to satisfy its future common stock commitments through the issuance of authorized but unissued shares of common stock.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Dr. Arnold S. Lippa and Jeff E. Margolis, officers and directors of the Company since March 22, 2013, have indirect ownership interests and managing memberships in Aurora Capital LLC (“Aurora”) through interests held in its members, and Jeff. E. Margolis is also an officer of Aurora. Aurora is a boutique investment banking firm specializing in the life sciences sector that is also a full-service brokerage firm. A description of advances and notes payable to officers is provided at Note 4.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Pending or Threatened Legal Action and Claims By letter dated May 18, 2018, the Company received notice from counsel claiming to represent TEC Edmonton and The Governors of the University of Alberta, which purported to terminate, effective December 12, 2017, the license agreement dated May 9, 2007 between the Company and The Governors of the University of Alberta. The license relates to the use of ampakines for the treatment of various respiratory disorders. The Company, through its counsel, disputed any grounds for termination and notified the representative that it invoked Section 13 of that license agreement, which mandates a meeting to be attended by individuals with decision-making authority to attempt in good faith to negotiate a resolution to the dispute. In February 2019, the Company and TEC Edmonton tentatively agreed to terms acceptable to all parties to establish a new license agreement and the form of a new license agreement. However, the Company has re-evaluated that portion of its ampakine program and has decided not to enter into a new agreement, at this time. The lack of entry into a new agreement at this time does not affect the Company’s other ampakine programs and permits the Company to reallocate resources to those programs, including, but not limited to ADHD, SCI, FXS and others. By e-mail dated July 21, 2016, the Company received a demand from an investment banking consulting firm that represented the Company in 2012 in conjunction with the Pier transaction alleging that $225,000 is due and payable for investment banking services rendered. Such amount has been included in accrued expenses at September 30, 2019 and December 31, 2018. The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s consolidated financial statements as of September 30, 2019 and December 31, 2018 with respect to such matters, including, specifically, the matters noted above. The Company intends to vigorously defend itself if any of the matters described above results in the filing of a lawsuit or formal claim. Significant Agreements and Contracts Consulting Agreement Richard Purcell, the Company’s Senior Vice President of Research and Development since October 15, 2014, provides his services to the Company on a month-to-month basis through his consulting firm, DNA Healthlink, Inc., through which the Company has contracted for his services, for a monthly cash fee of $12,500. Additional information with respect to shares of common stock that have been issued to Mr. Purcell is provided at Note 6. Cash compensation expense pursuant to this agreement totaled $112,500 and $37,500 for the nine months and three months ended September 30, 2019 and 2018, which is included in research and development expenses in the Company’s consolidated statements of operations for such periods. Employment Agreements On October 12, 2018, Dr. Lippa was named Interim President and Interim Chief Executive Officer to replace Dr. Manuso who resigned effective September 30, 2018. Dr. Lippa continues to serve as the Company’s Executive Chairman and as a member of the Board of Directors. Also, on August 18, 2015, Dr. Lippa was named Chief Scientific Officer of the Company, and the Company entered into an employment agreement with Dr. Lippa in that capacity. Pursuant to the agreement, which is for an initial term through September 30, 2018 (and which automatically extended on September 30, 2018 and September 30, 2019 and will automatically extend annually, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date), Dr. Lippa received an annual base salary of $300,000. Dr. Lippa is also eligible to earn a performance-based annual bonus award of up to 50% of his base salary, based upon the achievement of annual performance goals established by the Board of Directors in consultation with the executive prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. Additionally, Dr. Lippa was granted stock options to acquire 30,769 shares of common stock of the Company and is eligible to receive additional awards under the Company’s Plans at the discretion of the Board of Directors. Dr. Lippa is also entitled to receive, until such time as the Company establishes a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance policy. Dr. Lippa is also entitled to be reimbursed for business expenses. Additional information with respect to the stock options granted to Dr. Lippa is provided at Note 6. Cash compensation accrued pursuant to this agreement totaled $254,700 and $84,900 for the nine months and three months ended September 30, 2019 and 2018, respectively, and $339,600 for the fiscal year ended December 31, 2018 which amounts are included in accrued compensation and related expenses in the Company’s consolidated balance sheet at September 30, 2019 and December 31, 2018, and in research and development expenses in the Company’s consolidated statement of operations. Dr. Lippa does not receive any additional compensation for serving as Executive Chairman and on the Board of Directors. On August 18, 2015, the Company also entered into an employment agreement with Jeff E. Margolis, in his role as Vice President, Secretary and Treasurer. Pursuant to the agreement, which was for an initial term through September 30, 2016 (and which has automatically extended on each subsequent anniversary and will continue to automatically extend annually upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date). At the inception of the employment agreement, Mr. Margolis was granted stock options to acquire 30,769 shares of common stock of the Company and remians eligible to receive additional awards under the Company’s Plans at the discretion of the Board of Directors. Mr. Margolis is also entitled to receive, until such time as the Company establishes a group health plan for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance policy. Mr. Margolis is also entitled to be reimbursed for business expenses. Mr. Margolis’ employment agreement was amended effective July 1, 2017. The employment agreement amendment called for payment in three installments in cash of the $60,000 bonus granted on June 30, 2015. A minimum of $15,000 was to be payable in cash as follows: (a) $15,000 payable in cash upon the next closing (after July 1, 2017) of any financing in excess of $100,000 (b) $15,000 payable by the end of the following month assuming cumulative closings (beginning with the closing that triggered (a)) in excess of $200,000 and (c) $30,000 payable in cash upon the next closing of any financing in excess of an additional $250,000. The conditions of (a), (b) and (c) above were met as of December 31, 2017, however Mr. Margolis has waived the Company’s obligation to make any payments of the cash bonus until the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. Mr. Margolis currently receives an annual base salary of $300,000, and is also eligible to receive performance-based annual bonus awards ranging from $65,000 to $125,000, based upon the achievement of annual performance goals established by the Board of Directors in consultation with Mr. Margolis prior to the start of such fiscal year, or any amount at the discretion of the Board of Directors. Additional information with respect to the stock options granted to Mr. Margolis is provided at Note 6. Recurring cash compensation accrued pursuant to this amended agreement totaled $241,200 and $80,400 for the nine months and three months ended September 30, 2019 and 2018, respectively, and $321,600 for the fiscal year ended December 31, 2018. Such amounts are included in accrued compensation and related expenses in the Company’s consolidated balance sheet at September 30, 2019 and December 31, 2018 respectively, and in general and administrative expenses in the Company’s consolidated statement of operations. The employment agreements between the Company and each of Dr. Lippa and Mr. Margolis (prior to the 2017 amendment), respectively, provided that the payment obligations associated with the first year base salary were to accrue, but no payments were to be made, until at least $2,000,000 of net proceeds from any offering or financing of debt or equity, or a combination thereof, was received by the Company, at which time scheduled payments were to commence. Dr. Lippa and Mr. Margolis (who are each also directors of the Company), and prior to his resignation, Dr. James S. Manuso, have each agreed, effective as of August 11, 2016, to continue to defer the payment of such amounts indefinitely, until such time as the Board of Directors of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis. Additionally, on December 9, 2017, Dr. Lippa, Mr. Margolis and Dr. Manuso forgave accrued compensation that had accrued through September 30, 2017 in exchange for stock options. University of Alberta License Agreement On May 9, 2007, the Company entered into a license agreement, as amended, with the University of Alberta granting the Company exclusive rights to practice patents held by the University of Alberta claiming the use of ampakines for the treatment of various respiratory disorders. The Company agreed to pay the University of Alberta a licensing fee and a patent issuance fee, which were paid, and prospective payments consisting of a royalty on net sales, sublicense fee payments, maintenance payments and milestone payments. The prospective maintenance payments commence on the enrollment of the first patient into the first Phase 2B clinical trial and increase upon the successful completion of the Phase 2B clinical trial. As the Company does not at this time anticipate scheduling a Phase 2B clinical trial in the near term, no maintenance payments to the University of Alberta are currently due and payable, nor are any maintenance payments expected to be due in the near future in connection with the license agreement. On May 18, 2018, the Company received a letter from counsel claiming to represent TEC Edmonton and The Governors of the University of Alberta, which purported to terminate, effective December 12, 2017, the license agreement dated May 9, 2007 (as subsequently amended) between the Company and The Governors of the University of Alberta. The Company, through its counsel, disputed any grounds for termination and notified the representative that it invoked Section 13 of that license agreement, which mandates a meeting to be attended by individuals with decision-making authority to attempt in good faith to negotiate a resolution to the dispute. In February 2019, the Company and TEC Edmonton tentatively agreed to terms acceptable to all parties to establish a new license agreement and the form of a new license agreement. However, the Company has re-evaluated that portion of its ampakine program and has decided not to enter into a new agreement, at this time. The lack of entry into a new agreement at this time does not affect the Company’s other ampakine programs and permits the Company to reallocate resources to those programs, including, but not limited to ADHD, SCI, FXS and others. University of Illinois 2014 Exclusive License Agreement On June 27, 2014, the Company entered into an Exclusive License Agreement (the “2014 License Agreement”) with the University of Illinois, the material terms of which were similar to a License Agreement between the parties that had been previously terminated on March 21, 2013. The 2014 License Agreement became effective on September 18, 2014, upon the completion of certain conditions set forth in the 2014 License Agreement, including: (i) the payment by the Company of a $25,000 licensing fee, (ii) the payment by the Company of outstanding patent costs aggregating $15,840, and (iii) the assignment to the University of Illinois of rights the Company held in certain patent applications, all of which conditions were fulfilled. The 2014 License Agreement granted the Company (i) exclusive rights to several issued and pending patents in numerous jurisdictions and (ii) the non-exclusive right to certain technical information that is generated by the University of Illinois in connection with certain clinical trials as specified in the 2014 License Agreement, all of which relate to the use of cannabinoids for the treatment of sleep related breathing disorders. The Company is developing dronabinol (Δ9-tetrahydrocannabinol), a cannabinoid, for the treatment of OSA, the most common form of sleep apnea. The 2014 License Agreement provides for various commercialization and reporting requirements commencing on June 30, 2015. In addition, the 2014 License Agreement provides for various royalty payments, including a royalty on net sales of 4%, payment on sub-licensee revenues of 12.5%, and a minimum annual royalty beginning in 2015 of $100,000, which is due and payable on December 31 of each year beginning on December 31, 2015. The minimum annual royalty obligation of $100,000 due on December 31, 2018, was extended to February 28, 2019, when such payment obligation was paid by the Company. One-time milestone payments may become due based upon the achievement of certain development milestones. $350,000 will be due within five days after the dosing of the first patient is a Phase III human clinical trial anywhere in the world. $500,000 will be due within five days after the first NDA filing with FDA or a foreign equivalent. $1,000,000 will be due within twelve months of the first commercial sale. One-time royalty payments may also become due and payable. Annual royalty payments may also become due. In the year after the first application for market approval is submitted to the FDA or a foreign equivalent and until approval is obtained, the minimum annual royalty will increase to $150,000. In the year after the first market approval is obtained from the FDA or a foreign equivalent and until the first sale of a product, the minimum annual royalty will increase to $200,000. In the year after the first commercial sale of a product, the minimum annual royalty will increase to $250,000. For each of the nine month and three month periods ending September 30, 2019 and 2018, the Company recorded a charge to operations of $75,000 and $25,000, respectively, with respect to its minimum annual royalty obligation, which is included in research and development expenses in the Company’s consolidated statements of operations for the nine months and three months ended September 30, 2019 and 2018, respectively. Research Contract with the University of Alberta On January 12, 2016, the Company entered into a Research Contract with the University of Alberta in order to test the efficacy of ampakines at a variety of dosage and formulation levels in the potential treatment of Pompe Disease, apnea of prematurity and spinal cord injury, as well as to conduct certain electrophysiological studies to explore the ampakine mechanism of action for central respiratory depression. The Company agreed to pay the University of Alberta total consideration of approximately CAD$146,000 (approximately US$111,000), consisting of approximately CAD$85,000 (approximately US$65,000) of personnel funding in cash in four installments during 2016, to provide approximately CAD$21,000 (approximately US$16,000) in equipment, to pay patent costs of CAD$20,000 (approximately US$15,000), and to underwrite additional budgeted costs of CAD$20,000 (approximately US$15,000). The final amount payable in respect to this Research Contract of US$16,207 (CAD$21,222) was paid in US dollars in January 2018 and completed the payments under the contract. The conversion to US dollars above utilizes an exchange rate of approximately US$0.76 for every CAD$1.00. The University of Alberta received matching funds through a grant from the Canadian Institutes of Health Research in support of this research. Dr. John Greer, faculty member of the Department of Physiology, Perinatal Research Centre and Women & Children’s Health Research Institute at the University of Alberta collaborated on this research. The studies were completed in 2016. See “University of Alberta License Agreement” above for more information on the related license agreement. Summary of Principal Cash Obligations and Commitments The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of September 30, 2019, aggregating $1,211,200 License agreement amounts included in the 2019 column represents amounts contractually due from October 1, 2019 through December 31, 2019 (three months) and in each of the subsequent years, represents the full year. Employment agreement amounts included in the 2019 column represent amounts contractually due at from October 1, 2019 through September 30, 2020 (twelve months) when such contracts expire unless extended pursuant to the terms of the contracts. Payments Due By Year Total 2019 2020 2021 2022 2023 License agreements $ 425,000 $ 25,000 $ 100,000 $ 100,000 $ 100,000 $ 100,000 Litigation settlement 125,000 $ 125,000 - - - - Employment agreements (1) 661,200 165,300 495,900 - - - Total $ 1,211,200 $ 315,300 $ 595,900 $ 100,000 $ 100,000 $ 100,000 (1) The payment of such amounts has been deferred indefinitely, as described above at “Employment Agreements.” The 2019 amounts include three months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts renewed on September 30, 2019 and the 2019 obligations include the three months of obligations through December 31, 2019.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events On October 22, 2019, the Company entered into a securities purchase agreement, a 10% Convertible Note (the “October 2019 Convertible Note”) and several other related agreements and documents. The October 2019 Convertible Note matures on July 22, 2020, provided for net proceeds to the Company of $54,500 which was received by the Company on October 28, 2019, and has a face amount of $60,000, bears interest at 10% per year, had an original issue discount of $1,750 and capitalized note costs of $3,750 (for legal and due diligence fees of the Holder of the October 2019 Convertible Note). The holder of the October 2019 Convertible Note also received 10,000 restricted shares of the Company’s common stock as commitment shares and a warrant to purchase 175,000 shares of the Company’s common stock, exercisable at $0.50 per share of common stock for five years. The October 2019 Convertible Note may be prepaid at the option of the Company, inclusive of accrued interest, by the Company subject to prepayment premium factors as described in the definitive documents and may not be prepaid after the 180th day. Subject to certain limitations, the October 2019 Convertible Note may be converted by the holder at 60% of the lowest traded price of the Company’s common stock, subject to a minimum trade size of 100 shares and a minimum daily trading volume of at least 100 shares, for the twenty (20) consecutive trading days prior to such conversion. In addition, the holder has certain redemption rights in the event of a subsequent financing and other rights. Pursuant to the terms of the definitive transaction documents, the Company must reserve that number of shares of common stock from its authorized but unissued shares that is six (6) times the number of shares of common stock into which the October 2019 Convertible Note may convert. At inception the Company reserved 1,935,000 shares in connection with the transaction. On November 4, 2019, the Company entered into a securities purchase agreement, a 10% Convertible Note (the “November 2019 Convertible Note”) and several other related agreements and documents. The November 2019 Convertible Note has a face amount of $170,000, matures on November 4, 2020, bears interest at 10% per year and resulted in net proceeds to the Company of $147,900, after taking into account capitalized note costs of $8,500 and an original issue discount of $13,600. There were no warrants or commitment shares issued with respect to the November 2019 Convertible Note. The November 2019 Convertible Note may be prepaid subject to prepayment premium factors as described in the definitive documents and may not be prepaid after the 180th day. The holder may convert, at any time, the November 2019 Convertible Note at the holder’s option into shares of the Company’s common stock at a price that is 60% of the lowest trading price, taking into consideration only trades of 100 shares or more, for the twenty (20) consecutive trading days prior to and inclusive of the conversion date of such conversion. Pursuant to the terms of the definitive transaction documents, at inception, the Company created an initial reserve of 5,200,000 shares of common stock in connection with this transaction from its authorized but unissued shares and must maintain a reserve at all times that is five (5) times the number of shares of common stock into which the October 2019 Convertible Note may convert. On November 12, 2019 the holder of the April 2019 Convertible Note (See Note 4. Notes Payable - Convertible Notes Payable

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.
Concentration of Risk	Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high credit quality financial institutions. The Company’s research and development efforts and potential products rely on licenses from research institutions and if the Company loses access to these technologies or applications, its business could be substantially impaired.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid short-term investments with maturities of less than three-months when acquired to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The authoritative guidance with respect to fair value of financial instruments established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, advances on research grants and accounts payable and accrued expenses) are considered by the Company to be representative of the respective fair values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd., formerly known as Samyang Optics Co. Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective fair values of such instruments due to the short-term nature of those instruments and their terms.
Convertible Notes Payable	Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants or a beneficial conversion feature, the convertible notes and warrants are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued at fair value in connection with and at the time of such financing. The value of debt discounts such as warrants, beneficial conversion features and original issue discounts are recorded as contra debt and amortized into interest expense over the life of the notes.
Extinguishment of Debt	Extinguishment of Debt The Company accounts for the extinguishment of debt in accordance with GAAP by comparing the carrying value of the debt to the fair value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs.
Equipment	Equipment Equipment is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, which range from three to five years. All equipment was fully depreciated as of September 30, 2019.
Prepaid Insurance	Prepaid Insurance Long-term prepaid insurance represents the premium paid in March 2014 for directors’ and officers’ insurance tail coverage, which is being amortized on a straight-line basis over the policy period of six years. The amount amortizable in the ensuing twelve- month period is recorded as a current asset in the Company’s condensed consolidated balance sheet at each reporting date. As of September 30, 2019, all such prepaid amounts have been reclassified as current since the policy will expire within one year.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets The Company reviews its long-lived assets, including long-term prepaid insurance, for impairment whenever events or changes in circumstances indicate that the total amount of an asset may not be recoverable, but at least annually. An impairment loss is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s carrying amount. The Company has not deemed any long-lived assets as impaired at September 30, 2019.
Stock-based Awards	Stock-Based Awards The Company periodically issues common stock and stock options to officers, directors, outside consultants and vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers, directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated financial statements over the vesting period of the awards. The fair value of stock options granted as stock-based payments is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk- free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. There were no stock or stock option grants during the nine months ended September 30, 2019. For stock options requiring an assessment of value during the nine months ended September 30, 2018, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 2.56 % Expected dividend yield 0 % Expected volatility 185.41 % Expected life 4.5 The Company recognizes the fair value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option and warrant exercises. There were no stock options exercised during the nine months ended September 30, 2019 and 2018.
Income Taxes	Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of September 30, 2019, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of September 30, 2019, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.
Foreign Currency Transactions	Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations.
Research and Development	Research and Development Research and development costs include compensation paid to management directing the Company’s research and development activities, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and product candidates. Research and development costs incurred by the Company under research grants are expensed as incurred over the life of the underlying contracts, unless the terms of the contract indicate that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. On May 6, 2016, the Company made an advance payment to Duke University with respect to the Phase 2A clinical trial of CX1739. At September 30, 2019, an asset balance of $48,912 remained from the advance payment.
License Agreements	License Agreements Obligations incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate period, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Payments of such liabilities are made in the ordinary course of business.
Patent Costs	Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses.
Earnings Per Share	Earnings per Share The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At September 30, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. September 30, 2019 2018 Series B convertible preferred stock 11 11 Convertible notes payable 867,200 16,061 Common stock warrants 2,016,043 1,703,229 Common stock options 4,287,609 4,323,317 Total 7,170,863 5,507,312
Reclassifications	Reclassifications Certain comparative figures in 2018 have been reclassified to conform to the current nine month and three month presentation. These reclassifications were immaterial, both individually and in the aggregate.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Fair Value of Option Estimated Using Black-Scholes Pricing Model with Valuation Assumptions	For stock options requiring an assessment of value during the nine months ended September 30, 2018, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model using the following assumptions: Risk-free interest rate 2.56 % Expected dividend yield 0 % Expected volatility 185.41 % Expected life 4.5
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	At September 30, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. September 30, 2019 2018 Series B convertible preferred stock 11 11 Convertible notes payable 867,200 16,061 Common stock warrants 2,016,043 1,703,229 Common stock options 4,287,609 4,323,317 Total 7,170,863 5,507,312

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2019
Schedule of Convertible Notes Payable	The 2018 Convertible Notes and 2019 Q1 Convertible Notes consist of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of notes payable $ 190,000 $ 80,000 Discount associated with issuance of warrants net of amortization of $82,159 as of September 30, 2019 and $8,379 as of December 31,2018 - (27,968 ) Accrued interest payable 13,121 401 $ 203,121 $ 52,433 The remaining outstanding Original Convertible Notes (including those for which default notices have been received) consist of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of notes payable $ 125,000 $ 125,000 Accrued interest payable 76,920 62,233 $ 201,920 $ 187,233
Summary of Note Payable to Related Party	Note payable to SY Corporation consists of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 351,188 315,307 Foreign currency transaction adjustment (27,775 ) 29,360 $ 723,187 $ 744,441
August 2019 Convertible Note [Member]
Schedule of Convertible Notes Payable	The table below provides a summary of the August 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 55,000 Debt discounts, net of amortization of $8,504 (46,496 ) Accrued coupon interest 648 $ 9,152
May 2019 Convertible Note [Member]
Schedule of Convertible Notes Payable	The table below provides a summary of the May 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 50,000 Debt discounts, net of amortization of $19,072 (31,149 ) Accrued coupon interest 1,876 $ 20,727
April 2019 Convertible Note [Member]
Schedule of Convertible Notes Payable	The table below provides a summary of the April 2019 Convertible Note as of September 30, 2019. Principal amount of note payable $ 58,500 Debt discounts, net of amortization of $21,238 (27,211 ) Accrued coupon interest 2,859 $ 34,148

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of Warrants Activity	A summary of warrant activity for the nine months ended September 30, 2019 is presented below. Weighted Average Weighted Remaining Number of Average Contractual Shares Exercise Price Life (in Years) Warrants outstanding and exerciable at December 31, 2018 1,783,229 $ 2.20393 3.06 Issued 302,372 0.95908 Expired (69,558 ) 2.65928 Warrants outstanding and exercisable at September 30, 2019 2,016,043 $ 1.99011 2.73 A summary of warrant activity for the nine months ended September 30, 2018 is presented below. Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding and exercisable at December 31, 2017 1,464,415 $ 2.68146 3.73 Issued 238,814 1.57500 Warrants outstanding and exercisable at September 30, 2018 1,703,229 $ 2.52632 4.08
Summary of Stock Option Activity	A summary of stock option activity for the nine months ended September 30, 2019 is presented below. Number of Weighted Weighted Options outstanding and exercisable at December 31, 2018 4,344,994 $ 3.7634 7.38 Expired (57,385 ) (15.6139 ) Options outstanding and exercisable at September 30, 2019 4,287,609 $ 3.3798 5.23 A summary of stock option activity for the nine months ended September 30, 2018 is presented below. Number of Weighted Weighted Options outstanding and exercisable at December 31, 2017 3,996,167 $ 3.7634 6.30 Granted 327,150 1.1267 4.50 Options outstanding and exercisable at September 30, 2018 4,323,317 $ 3.5855 6.17
Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable	The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2019: Exercise Price Warrants (Shares) Warrants (Shares) Expiration Date $ 0.5000 150,000 150,000 August 19, 2024 $ 1.0000 916,217 916,217 September 20, 2022 $ 1.1800 42,372 42,372 May 17, 2022 $ 1.5000 190,000 190,000 December 30, 2023 $ 1.5620 130,284 130,284 December 31, 2021 $ 1.5750 238,814 238,814 April 30, 2023 $ 2.7500 8,000 8,000 September 20, 2022 $ 4.8750 108,594 108,594 September 30, 2020 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 2,016,043 2,016,043 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2018: Exercise Price Warrants Outstanding Warrants Exercisable Expiration Date $ 1.0000 916,217 916,217 September 20, 2022 $ 1.2870 41,002 41,002 April 17, 2019 $ 1.5620 130,284 130,284 December 31, 2021 $ 1,5750 238,814 238,814 April 30, 2023 $ 2.7500 8,000 8000 September 20, 2022 $ 4.8500 5,155 5,155 September 23, 2019 $ 4.8750 108,594 108,594 September 30, 2020 $ 5.0000 5,000 5,000 September 22, 2019 $ 5.1025 10,309 10,309 January 29, 2019 $ 6.5000 8,092 8,092 February 4, 2019 $ 6.8348 145,758 145,758 September 30, 2020 $ 7.9300 86,004 86,004 February 28, 2021 1,703,229 1,703,229
Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable	The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2019: Exercise Price Options Outstanding Options Exercisable Expiration Date $ 0.7000 21,677 21,677 November 21, 2023 $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,287,609 4,287,609 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2018: Exercise Price Options Outstanding Options Exercisable Expiration Date $ 1.1200 310,388 310,388 April 5, 2023 $ 1.2500 16,762 16,762 December 7, 2022 $ 1.3500 34,000 34,000 July 28, 2022 $ 1.4500 1,849,418 1,849,418 December 9, 2027 $ 1.4500 100,000 100,000 December 9, 2027 $ 2.0000 285,000 285,000 June 30, 2022 $ 2.0000 25,000 25,000 July 26, 2022 $ 3.9000 395,000 395,000 January 17, 2022 $ 4.5000 7,222 7,222 September 2, 2021 $ 5.6875 89,686 89,686 June 30, 2020 $ 5.7500 2,608 2,608 September 12, 2021 $ 6.4025 27,692 27,692 August 18, 2020 $ 6.4025 129,231 129,231 August 18, 2022 $ 6.4025 261,789 261,789 August 18, 2025 $ 6.8250 8,791 8,791 December 11, 2020 $ 7.3775 523,077 523,077 March 31, 2021 $ 8.1250 169,231 169,231 June 30, 2022 $ 13.0000 7,385 7,385 March 13, 2019 $ 13.0000 3,846 3,846 April 14, 2019 $ 13.9750 3,385 3,385 March 14, 2024 $ 15.4700 7,755 7,755 April 8, 2020 $ 15.9250 2,462 2,462 February 28, 2024 $ 16.0500 46,154 46,154 July 17, 2019 $ 16.6400 1,538 1,538 January 29, 2020 $ 19.5000 9,487 9,487 July 17, 2022 $ 19.5000 6,410 6,410 August 10, 2022 4,323,317 4,323,317

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Summary of Principal Cash Obligations and Commitments	Employment agreement amounts included in the 2019 column represent amounts contractually due at from October 1, 2019 through September 30, 2020 (twelve months) when such contracts expire unless extended pursuant to the terms of the contracts. Payments Due By Year Total 2019 2020 2021 2022 2023 License agreements $ 425,000 $ 25,000 $ 100,000 $ 100,000 $ 100,000 $ 100,000 Litigation settlement 125,000 $ 125,000 - - - - Employment agreements (1) 661,200 165,300 495,900 - - - Total $ 1,211,200 $ 315,300 $ 595,900 $ 100,000 $ 100,000 $ 100,000 (1) The payment of such amounts has been deferred indefinitely, as described above at “Employment Agreements.” The 2019 amounts include three months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts renewed on September 30, 2019 and the 2019 obligations include the three months of obligations through December 31, 2019.

Business (Details Narrative)

Business (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses	$ 469,844	$ 477,213	$ 540,332	$ 535,774	$ 635,363	$ 746,679	$ 1,487,389	$ 1,917,817	$ 2,591,790
Negative operating cash flows							313,691	199,966	427,368
Cash and cash equivalents	94						94		33,284
Stockholders' deficiency	$ 7,039,381	$ 6,617,038	$ 6,227,775	$ 5,359,154	$ 5,069,128	$ 4,977,254	$ 7,039,381	$ 5,359,154	$ 5,733,255	$ 4,355,384

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Number of stock or stock options granted		327,150
Stock options exercised
Advance payment on research contract	$ 48,912		$ 48,912
Minimum [Member]
Estimated useful lives of equipment	P3Y
Maximum [Member]
Estimated useful lives of equipment	P5Y

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Fair Value of Option Estimated Using Black-Scholes Pricing Model with Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Risk-free interest rate	2.56%
Expected dividend yield	0.00%
Expected volatility	185.41%
Expected life	4 years 6 months

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share	7,170,863	5,507,312
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	2,016,043	1,703,229
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	4,287,609	4,323,317
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	867,200	16,061
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	11	11

Notes Payable (Details Narrativ

Notes Payable (Details Narrative)	Aug. 19, 2019USD ($)TradingDays$ / sharesshares	May 17, 2019USD ($)TradingDays$ / sharesshares	Apr. 24, 2019USD ($)TradingDays$ / sharesshares	Mar. 14, 2019USD ($)	Mar. 06, 2019USD ($)	Feb. 27, 2019USD ($)	Jan. 02, 2019USD ($)	Jun. 25, 2012USD ($)	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Jun. 25, 2012KRW (₩)
Debt instrument interest rate										10.00%		10.00%
Debt maturity date								Jun. 25, 2013
Debt instrument original issue discount									$ 104,858		$ 104,858		$ 27,969
Common stock, par value | $ / shares									$ 0.001		$ 0.001		$ 0.001
Initial value of note									$ 42,406		$ 42,406		$ 38,292
Interest expense									70,168	$ 35,161	221,813	$ 96,230
Accrued interest									17,406		17,406		13,292
Stockholder's percentage								20.00%								20.00%
Percentage of convertible notes payable								12.00%								12.00%
SY Corporation [Member]
Debt face amount								$ 400,000
Interest expense									12,092	12,092	35,881	35,881
SY Corporation [Member] | Won [Member]
Debt face amount | ₩																₩ 465,000,000
Dr. Arnold S [Member]
Interest expense									2,589	3,319	7,683	9,517
Dr. James S. Manuso [Member]
Interest expense									$ 3,886	$ 3,564	$ 11,530	$ 9,754
Warrant [Member]
Debt instrument interest rate		8.89%
Convertible Notes Payable [Member]
Warrant to purchase shares | shares									27,936		27,936
Warrant exercise price | $ / shares									$ 11.375		$ 11.375
Extended maturity date									Sep. 15, 2016		Sep. 15, 2016
Accrued interest									$ 95,425		$ 95,425		$ 62,635
Nine Monthly Installments [Member]
Debt periodic payments											7,120
August 2019 Convertible Note [Member]
Debt issuance costs	$ 2,500
Debt instrument original issue discount	$ 5,000								46,496		46,496
Warrant to purchase shares | shares	150,000
Commitment shares | shares	7,500
Proceeds from convertible debt	$ 47,500
Debt instrument, convertible, conversion price | $ / shares	$ 0.50
Debt instrument, convertible, closing price | $ / shares	$ 0.50
Debt instrument, conversion percentage	0.60
Debt instrument, convertible, threshold trading days | TradingDays	20
Debt conversion, description	Subject to certain limitations and adjustments as described in the August 2019 Convertible Note, the holder may convert the August 2019 Convertible Note at a fixed conversion price of $0.50 per share of common stock, provided that from the date that is six months after the issuance date, the conversion price shall be the lower of (a) $0.50 or (b) 60% multiplied by the lowest closing price of the common stock during the twenty (20) consecutive trading days prior to conversion. The Company evaluated all of the terms of the August 2019 Convertible Note and determined that, in accordance with ASC 815, there were no derivatives to be bifurcated or separately valued. However, there were five features of the August 2019 Convertible Note and the related securities purchase agreement that required valuation. They were: (i) the debt issuance costs of $2,500, (ii) the intrinsic value of the beneficial conversion feature, (iii) the value of the warrant, (iv) the original issue discount of $5,000, and (v) the value of the Commitment Shares. The Company amortizes each of these five on a straight-line basis over the life of the August 2019 Convertible Note.
Debt beneficial conversion feature	$ 16,500
Shares issued price per share | $ / shares	$ 0.65
Warrant term	5 years
Value of warrants to purchase shares	$ 93,450
Warrant fair value	30,440
Commitment shares fair value	$ 1,588
August 2019 Convertible Note [Member] | Warrant [Member]
Debt instrument interest rate	64.08%
August 2019 Convertible Note [Member] | Commitment Shares [Member]
Debt instrument interest rate	3.34%
August 2019 Convertible Note [Member] | One Warrant [Member]
Warrant exercise price | $ / shares	$ 0.623
August 2019 Convertible Note [Member] | Risk Free Interest Rate [Member]
Warrants and rights outstanding, measurement input	1.47
August 2019 Convertible Note [Member] | Measurement Input, Volatility [Member]
Warrants and rights outstanding, measurement input	175.5
August 2019 Convertible Note [Member] | Tranches [Member]
Debt instrument interest rate	10.00%
Debt face amount	$ 55,000
Debt maturity date	May 19, 2020
May 2019 Convertible Note [Member]
Debt instrument interest rate		13.56%
Debt issuance costs		$ 2,000
Debt instrument original issue discount		5,000							$ 31,149		$ 31,149
Proceeds from convertible debt		$ 43,000
Debt instrument, convertible, conversion price | $ / shares		$ 0.25
Debt instrument, convertible, closing price | $ / shares		$ 0.25
Debt instrument, conversion percentage		0.61
Debt instrument, convertible, threshold trading days | TradingDays		25
Debt beneficial conversion feature		$ 286,000
Warrant exercise price | $ / shares		$ 1.18
Shares issued price per share | $ / shares		$ 0.84
Warrant term		3 years
Warrant fair value		$ 32,796
Warrant exercisable, shares | shares		42,373
May 2019 Convertible Note [Member] | One Warrant [Member]
Shares issued price per share | $ / shares		$ 0.774
May 2019 Convertible Note [Member] | Risk Free Interest Rate [Member]
Warrants and rights outstanding, measurement input		2.15
May 2019 Convertible Note [Member] | Measurement Input, Volatility [Member]
Warrants and rights outstanding, measurement input		210.19
May 2019 Convertible Note [Member] | Tranches [Member]
Debt instrument interest rate		10.00%
May 2019 Convertible Note [Member] | Tranches [Member] | Maximum [Member]
Debt face amount		$ 150,000
May 2019 Convertible Note [Member] | Tranche One [Member]
Debt face amount		$ 50,000
Debt maturity date		May 17, 2020
Debt instrument, convertible, conversion price | $ / shares		$ 0.125							$ 0.175		$ 0.175
Debt instrument, conversion percentage											0.50
Converted into common stock | shares		400,000									296,438
Common stock, par value | $ / shares		$ 0.001
Beneficial Conversion Feature [Member]
Debt instrument interest rate		77.55%
April 2019 Convertible Note [Member]
Debt instrument interest rate			10.00%
Debt face amount			$ 58,500
Debt maturity date			Apr. 24, 2020
Debt issuance costs			$ 3,500
Debt instrument original issue discount									$ 27,211		$ 27,211
Proceeds from convertible debt			$ 50,000
Debt instrument, convertible, conversion price | $ / shares			$ 0.3964
Debt instrument, convertible, closing price | $ / shares			$ 0.65
Debt instrument, conversion percentage			0.61
Debt instrument, convertible, threshold trading days | TradingDays			20
Debt beneficial conversion feature			$ 44,950
Converted into common stock | shares			147,541
2019 Q1 Convertible Notes [Member]
Debt instrument interest rate				10.00%	10.00%	10.00%	10.00%		10.00%		10.00%
Debt face amount				$ 100,000	$ 100,000	$ 100,000	$ 10,000
Debt maturity date				Apr. 30, 2019	Apr. 30, 2019	Apr. 30, 2019	Feb. 28, 2019				Feb. 28, 2019
Debt instrument original issue discount									$ 45,812		$ 45,812
Warrant to purchase shares | shares									110,000		110,000
Warrant exercise price | $ / shares									$ 1.50		$ 1.50
Value of warrants to purchase shares									$ 78,780		$ 78,780
Fair value of convertible note and warrant											188,780
Initial value of note									64,188		64,188
Additional debt interest expense									$ 2,811		$ 6,653
Debt instrument, description											The 2019 Convertible Note that matured on February 28, 2019 was not paid and remains outstanding and continues to accrue interest. The 2019 Convertible Notes that matured on April 30, 2019 were not paid and remain outstanding and continue to accrue interest.
2018 Convertible Notes [Member] | Investor [Member]
Debt instrument interest rate									10.00%		10.00%		10.00%
Debt face amount													$ 80,000
Debt maturity date													Feb. 28, 2019
Debt instrument original issue discount													$ 36,347
Warrant to purchase shares | shares													80,000
Warrant exercise price | $ / shares													$ 1.50
Value of warrants to purchase shares													$ 68,025
Fair value of convertible note and warrant													148,025
Initial value of note													43,653
Additional debt interest expense									$ 2,044		$ 6,067
Convertible Notes Payable [Member] | Investor [Member]
Debt instrument interest rate														10.00%	10.00%
Debt face amount														$ 579,500	$ 579,500
Warrant to purchase shares | shares														50,945	50,945
Warrant exercise price | $ / shares														$ 11.3750	$ 11.3750
Convertible Notes [Member]
Debt instrument interest rate									12.00%		12.00%
Debt periodic payments											$ 42,406		38,292
Accrued interest									$ 17,406		$ 17,406		$ 13,292
Original Convertible Notes [Member]
Converted into common stock | shares											17,810		16,460
Accrued interest									$ 76,920		$ 76,920		$ 62,233
Number of conversion into common shares attributable to accrued interest | shares											6,765		5,471
Other Short-Term Notes Payable [Member]
Debt instrument interest rate									9.00%		9.00%
Insurance premium									$ 61,746		$ 61,746
Short term borrowings									$ 27,997		$ 27,997		$ 8,907

Notes Payable - Schedule of Con

Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2019	Aug. 19, 2019	May 17, 2019	Dec. 31, 2018
Debt discounts, net of amortization	$ (104,858)			$ (27,969)
Accrued interest payable	17,406			13,292
Convertible notes payable, gross	469,067			239,666
August 2019 Convertible Note [Member]
Principal amount of notes payable	55,000
Debt discounts, net of amortization	(46,496)	$ (5,000)
Accrued coupon interest	648
Convertible notes payable, gross	9,152
May 2019 Convertible Note [Member]
Principal amount of notes payable	50,000
Debt discounts, net of amortization	(31,149)		$ (5,000)
Accrued coupon interest	1,876
Convertible notes payable, gross	20,727
April 2019 Convertible Note [Member]
Principal amount of notes payable	58,500
Debt discounts, net of amortization	(27,211)
Accrued coupon interest	2,859
Convertible notes payable, gross	34,148
2018 Convertible Notes and 2019 Q1 Convertible Notes [Member]
Principal amount of notes payable	190,000			80,000
Discount associated with beneficial conversion feature, net of amortization				(27,968)
Accrued interest payable	13,121			401
Convertible notes payable, gross	203,121			52,433
Original Convertible Notes [Member]
Principal amount of notes payable	125,000			125,000
Accrued interest payable	76,920			62,233
Convertible notes payable, gross	$ 201,920			$ 187,233

Notes Payable - Schedule of C_2

Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Amortization of debt discount	$ 119,793
August 2019 Convertible Note [Member]
Amortization of debt discount	8,504
May 2019 Convertible Note [Member]
Amortization of debt discount	19,072
April 2019 Convertible Note [Member]
Amortization of debt discount	21,238
2018 Convertible Notes and 2019 Q1 Convertible Notes [Member]
Amortization of discount associated with warrant	$ 82,159		$ 8,379

Notes Payable - Summary of Note

Notes Payable - Summary of Note Payable to Related Party (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Accrued interest payable	$ 17,406	$ 13,292
Total note payable	723,187	744,441
SY Corporation [Member]
Principal amount of note payable	399,774	399,774
Accrued interest payable	351,188	315,307
Foreign currency transaction adjustment	(27,775)	29,360
Total note payable	$ 723,187	$ 744,441

Settlement and Payment Agreem_2

Settlement and Payment Agreements (Details Narrative) - Salamandra, LLC [Member] - USD ($)	Nov. 30, 2019	Sep. 23, 2019	Sep. 30, 2019
Due to related party			$ 202,395
Debt settlement description		The agreement in principal calls for a payment of a minimum of $100,000 on or before November 30, 2019 assuming the Company has raised at least $600,000 by that date and thereafter calls for a payment of $50,000 per month until paid in full. If the Company does not make a scheduled payment, the agreement in principal would be deemed null and void.	The settlement agreement reduces the amount owed to a lump-sum payment of $125,000 payable by November 30, 2019, if by that date, the Company has raised an aggregate of at least $600,000 in working capital. Should the Company raise less than $600,000, the Company may pay 21% of the amount raised and cancel that portion of the debt. If the Company is unable to raise $600,000 by November 30, 2019, the settlement agreement becomes null and void. Upon receipt of the settlement payment, mutual releases will become effective with respect to the remaining amount of debt on that date.
Working capital			$ 202,400
Forecast [Member]
Repayment of debt	$ 125,000
On or Before November 30, 2019 [Member]
Debt periodic payment		$ 100,000
Thereafter [Member]
Debt periodic payment		$ 50,000

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	Sep. 30, 2019	Dec. 28, 2018	Dec. 09, 2017	Jan. 17, 2017	Mar. 31, 2016	Aug. 18, 2015	Jun. 30, 2015	Mar. 18, 2014	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Preferred stock, shares authorized	5,000,000								5,000,000
Preferred stock, par value	$ 0.001								$ 0.001
Preferred stock voting									Cumulative Convertible Preferred Stock (non-voting, "9% Preferred Stock")
Preferred stock, shares undesignated	3,505,800								3,505,800		3,505,800
Common stock, shares outstanding	3,879,576								3,879,576		3,872,076
Common stock reserved for future issuances	6,534,657								6,534,657
Common stock reserved for exercises of stock purchase options granted and warrants issued	6,303,652								6,303,652
Number of shares available for future issuances	43,452,954								43,452,954
Number of options and restricted stock granted during period										327,150
Stock option period									4 years 6 months
Common stock, shares authorized	65,000,000								65,000,000		65,000,000
Common stock, shares issued	3,879,576								3,879,576		3,872,076
2014 Equity Plan [Member]
Number of options and restricted stock granted during period								325,025
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member]
Option issued to purchase number of common stock							461,538
Stock option period							10 years
2015 Equity Plan [Member]
Fair value of market price per share	$ 0.45								$ 0.45	$ 0.7101
Stock warrant intrinsic value of exercisable
Deferred compensation expense
2015 Equity Plan [Member] | Board of Directors [Member]
Number of options and restricted stock granted during period		8,985,260	6,985,260	3,038,461	1,538,461	769,231
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member]
Number of options and restricted stock granted during period				1,500,000
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | Minimum [Member]
Number of options and restricted stock granted during period				1,538,461
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member] | Maximum [Member]
Number of options and restricted stock granted during period				3,038,461
2015 Stock and Stock Option Plan [Member] | Board of Directors [Member]
Common stock reserved for future issuances	4,490,578								4,490,578
Number of shares available for future issuances	42,918,394								42,918,394
Number of options and restricted stock granted during period		8,985,260	6,985,260
Common stock, shares authorized	65,000,000								65,000,000
Common stock, shares issued	3,879,576								3,879,576
2014 and 2015 Plans [Member]
Common stock reserved for future issuances	4,490,578								4,490,578
Conversions of Convertible Debt [Member]
Common stock reserved for future issuances	7,401,292								7,401,292
Conversions of Convertible Debt [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member]
Common stock reserved for future issuances	7,401,292								7,401,292
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	37,500								37,500		37,500
Preferred stock, par value	$ 0.001								$ 0.001		$ 0.001
Preferred stock shares issuable upon conversion, per share	0.00030								0.00030	$ 0.00030	$ 0.00030
Debt instrument, conversion price per share	$ 2,208.375								$ 2,208.375	2,208.375
Preferred stock shares issuable upon conversion	11								11		11
Preferred stock redemption amount	$ 25,001								$ 25,001		$ 25,001
Redeemed preferred stock price per share	$ 0.6667								$ 0.6667		$ 0.6667
Series B Convertible Preferred Stock [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member]
Common stock shares issuable upon conversion	11
Series A Junior Participating Preferred Stock [Member]
Preferred stock, shares designated	205,000								205,000		205,000
Series G 1.5% Convertible Preferred Stock [Member]
Preferred stock, shares designated	1,700								1,700		1,700
9% Cumulative Convertible Preferred Stock [Member]
Preferred stock, shares authorized	1,250,000								1,250,000		1,250,000
Common Stock [Member]
Common stock reserved for future issuances	7,383,482								7,383,482
Common Stock [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member]
Common stock reserved for future issuances	7,383,482								7,383,482
Pier Contingent Shares [Member]
Common stock reserved for future issuances	6,497								6,497
Pier Contingent Shares [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member]
Common stock reserved for future issuances	6,497								6,497
Common Stock Warrants [Member]
Fair value of market price per share	$ 0.45								$ 0.45	$ 0.7171
Stock warrant intrinsic value of exercisable	$ 7,500								$ 7,500
Common Stock One [Member] | 2015 Stock and Stock Option Plan [Member] | Board of Directors [Member]
Common stock reserved for future issuances	6,516,847								6,516,847

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Warrants Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Equity [Abstract]
Number of Warrants, Outstanding, Beginning balance	1,783,229	1,464,415
Number of Warrants, Issued	302,372	238,814
Number of Warrants, Expired	(69,558)
Number of Warrants, Outstanding, Ending balance	2,016,043	1,703,229
Weighted Average Exercise Price, Outstanding, Beginning	$ 2.20393	$ 2.68146
Weighted Average Exercise Price, Issued	0.95908	1.57500
Weighted Average Exercise Price, Expired	2.65928
Weighted Average Exercise Price, Outstanding, Ending	$ 1.99011	$ 2.52632
Warrants outstanding ,Weighted Average Remaining Contractual Life (in Years), Beginning	3 years 22 days	3 years 8 months 23 days
Warrants outstanding ,Weighted Average Remaining Contractual Life (in Years), Ending	2 years 8 months 23 days	4 years 29 days
Number of Warrants, Exercisable, Beginning balance	1,783,229	1,464,415
Number of Warrants, Exercisable, Ending balance	2,016,043	1,703,229
Weighted Average Exercise Price, Exercisable, Beginning	$ 2.20393	$ 2.68146
Weighted Average Exercise Price, Exercisable, Ending	$ 1.99011	$ 2.52632
Warrants exercisable, Weighted Average Remaining Contractual Life (in Years), Beginning	3 years 22 days	3 years 8 months 23 days
Warrants exercisable, Weighted Average Remaining Contractual Life (in Years), Ending	2 years 8 months 23 days	4 years 29 days

Stockholders' Deficiency - Summ

Stockholders' Deficiency - Summary of Stock Option Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Equity [Abstract]
Number of shares, Options outstanding, beginning balance	4,344,994	3,996,167
Number of shares, Options Expired	(57,385)
Number of shares, Options Granted		327,150
Number of shares, Options outstanding, ending balance	4,287,609	4,323,317
Weighted Average Exercise Price, Options outstanding, beginning balance	$ 3.7634	$ 3.7634
Weighted Average Exercise Price, Options Expired	(15.6139)
Weighted Average Exercise Price, Options Granted		1.1267
Weighted Average Exercise Price, Options outstanding, ending balance	$ 3.3798	$ 3.5855
Weighted Average Remaining Contractual Life (in Years), Options outstanding, beginning balance	7 years 4 months 17 days	6 years 3 months 19 days
Weighted Average Remaining Contractual Life (in Years), Options Granted		4 years 6 months
Weighted Average Remaining Contractual Life (in Years), Options outstanding, ending balance	5 years 2 months 23 days	6 years 2 months 1 day
Number of shares, Options exercisable beginning balance	4,344,994	3,996,167
Number of shares, Options exercisable ending balance	4,287,609	4,323,317
Weighted Average Exercise Price, Options exercisable beginning balance	$ 3.7634	$ 3.7634
Weighted Average Exercise Price, Options exercisable ending balance	$ 3.3798	$ 3.5855
Weighted Average Remaining Contractual Life (in Years), Options exercisable beginning balance	7 years 4 months 17 days	6 years 3 months 19 days
Weighted Average Remaining Contractual Life (in Years), Options exercisable ending balance	5 years 2 months 23 days	6 years 2 months 1 day

Stockholders' Deficiency - Sc_2

Stockholders' Deficiency - Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable (Details) - $ / shares	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Warrants, Outstanding (Shares)	2,016,043	1,783,229	1,703,229	1,464,415
Warrants, Exercisable (Shares)	2,016,043	1,783,229	1,703,229	1,464,415
Warrants [Member]
Warrants, Outstanding (Shares)	2,016,043		1,703,229
Warrants, Exercisable (Shares)	2,016,043		1,703,229
Exercise Price Range One [Member] | Warrants [Member]
Warrants, Exercise Price	$ 0.5000		$ 1
Warrants, Outstanding (Shares)	150,000		916,217
Warrants, Exercisable (Shares)	150,000		916,217
Warrants, Expiration Date	Aug. 19, 2024		Sep. 20, 2022
Exercise Price Range Two [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1		$ 1.2870
Warrants, Outstanding (Shares)	916,217		41,002
Warrants, Exercisable (Shares)	916,217		41,002
Warrants, Expiration Date	Sep. 20, 2022		Apr. 17, 2019
Exercise Price Range Three [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1.1800		$ 1.5620
Warrants, Outstanding (Shares)	42,372		130,284
Warrants, Exercisable (Shares)	42,372		130,284
Warrants, Expiration Date	May 17, 2022		Dec. 31, 2021
Exercise Price Range Four [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1.5000		$ 1.5750
Warrants, Outstanding (Shares)	190,000		238,814
Warrants, Exercisable (Shares)	190,000		238,814
Warrants, Expiration Date	Dec. 30, 2023		Apr. 30, 2023
Exercise Price Range Five [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1.5620		$ 2.7500
Warrants, Outstanding (Shares)	130,284		8,000
Warrants, Exercisable (Shares)	130,284		8,000
Warrants, Expiration Date	Dec. 31, 2021		Sep. 20, 2022
Exercise Price Range Six [Member] | Warrants [Member]
Warrants, Exercise Price	$ 1.5750		$ 4.8500
Warrants, Outstanding (Shares)	238,814		5,155
Warrants, Exercisable (Shares)	238,814		5,155
Warrants, Expiration Date	Apr. 30, 2023		Sep. 23, 2019
Exercise Price Range Seven [Member] | Warrants [Member]
Warrants, Exercise Price	$ 2.7500		$ 4.8750
Warrants, Outstanding (Shares)	8,000		108,594
Warrants, Exercisable (Shares)	8,000		108,594
Warrants, Expiration Date	Sep. 20, 2022		Sep. 30, 2020
Exercise Price Range Eight [Member] | Warrants [Member]
Warrants, Exercise Price	$ 4.8750		$ 5
Warrants, Outstanding (Shares)	108,594		5,000
Warrants, Exercisable (Shares)	108,594		5,000
Warrants, Expiration Date	Sep. 30, 2020		Sep. 22, 2019
Exercise Price Range Nine [Member] | Warrants [Member]
Warrants, Exercise Price	$ 6.8348		$ 5.1025
Warrants, Outstanding (Shares)	145,758		10,309
Warrants, Exercisable (Shares)	145,758		10,309
Warrants, Expiration Date	Sep. 30, 2020		Jan. 29, 2019
Exercise Price Range Ten [Member] | Warrants [Member]
Warrants, Exercise Price	$ 7.9300		$ 6.5000
Warrants, Outstanding (Shares)	86,004		8,092
Warrants, Exercisable (Shares)	86,004		8,092
Warrants, Expiration Date	Feb. 28, 2021		Feb. 4, 2019
Exercise Price Range Eleven [Member] | Warrants [Member]
Warrants, Exercise Price			$ 6.8348
Warrants, Outstanding (Shares)			145,758
Warrants, Exercisable (Shares)			145,758
Warrants, Expiration Date			Sep. 30, 2020
Exercise Price Range Twelve [Member] | Warrants [Member]
Warrants, Exercise Price			$ 7.9300
Warrants, Outstanding (Shares)			86,004
Warrants, Exercisable (Shares)			86,004
Warrants, Expiration Date			Feb. 28, 2021

Stockholders' Deficiency - Sc_3

Stockholders' Deficiency - Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Options Outstanding (Shares)	4,287,609	4,323,317	4,344,994	3,996,167
Options Exercisable (Shares)	4,287,609	4,323,317	4,344,994	3,996,167
Stock Option One [Member]
Options Exercise Price	$ 0.7000	$ 1.1200
Options Outstanding (Shares)	21,677	310,388
Options Exercisable (Shares)	21,677	310,388
Options, Expiration Date	Nov. 21, 2023	Apr. 5, 2023
Stock Option Two [Member]
Options Exercise Price	$ 1.1200	$ 1.2500
Options Outstanding (Shares)	310,388	16,762
Options Exercisable (Shares)	310,388	16,762
Options, Expiration Date	Apr. 5, 2023	Dec. 7, 2022
Stock Option Three [Member]
Options Exercise Price	$ 1.2500	$ 1.3500
Options Outstanding (Shares)	16,762	34,000
Options Exercisable (Shares)	16,762	34,000
Options, Expiration Date	Dec. 7, 2022	Jul. 28, 2022
Stock Option Four [Member]
Options Exercise Price	$ 1.3500	$ 1.4500
Options Outstanding (Shares)	34,000	1,849,418
Options Exercisable (Shares)	34,000	1,849,418
Options, Expiration Date	Jul. 28, 2022	Dec. 9, 2027
Stock Option Five [Member]
Options Exercise Price	$ 1.4500	$ 1.4500
Options Outstanding (Shares)	1,849,418	100,000
Options Exercisable (Shares)	1,849,418	100,000
Options, Expiration Date	Dec. 9, 2027	Dec. 9, 2027
Stock Option Six [Member]
Options Exercise Price	$ 1.4500	$ 2
Options Outstanding (Shares)	100,000	285,000
Options Exercisable (Shares)	100,000	285,000
Options, Expiration Date	Dec. 9, 2027	Jun. 30, 2022
Stock Option Seven [Member]
Options Exercise Price	$ 2	$ 2
Options Outstanding (Shares)	285,000	25,000
Options Exercisable (Shares)	285,000	25,000
Options, Expiration Date	Jun. 30, 2022	Jul. 26, 2022
Stock Option Eight [Member]
Options Exercise Price	$ 2	$ 3.9000
Options Outstanding (Shares)	25,000	395,000
Options Exercisable (Shares)	25,000	395,000
Options, Expiration Date	Jul. 26, 2022	Jan. 17, 2022
Stock Option Nine [Member]
Options Exercise Price	$ 3.9000	$ 4.5000
Options Outstanding (Shares)	395,000	7,222
Options Exercisable (Shares)	395,000	7,222
Options, Expiration Date	Jan. 17, 2022	Sep. 2, 2021
Stock Option Ten [Member]
Options Exercise Price	$ 4.5000	$ 5.6875
Options Outstanding (Shares)	7,222	89,686
Options Exercisable (Shares)	7,222	89,686
Options, Expiration Date	Sep. 2, 2021	Jun. 30, 2020
Stock Option Eleven [Member]
Options Exercise Price	$ 5.6875	$ 5.7500
Options Outstanding (Shares)	89,686	2,608
Options Exercisable (Shares)	89,686	2,608
Options, Expiration Date	Jun. 30, 2020	Sep. 12, 2021
Stock Option Twelve[Member]
Options Exercise Price	$ 5.7500	$ 6.4025
Options Outstanding (Shares)	2,608	27,692
Options Exercisable (Shares)	2,608	27,692
Options, Expiration Date	Sep. 12, 2021	Aug. 18, 2020
Stock Option Thirteen [Member]
Options Exercise Price	$ 6.4025	$ 6.4025
Options Outstanding (Shares)	27,692	129,231
Options Exercisable (Shares)	27,692	129,231
Options, Expiration Date	Aug. 18, 2020	Aug. 18, 2022
Stock Option Fourteen [Member]
Options Exercise Price	$ 6.4025	$ 6.4025
Options Outstanding (Shares)	129,231	261,789
Options Exercisable (Shares)	129,231	261,789
Options, Expiration Date	Aug. 18, 2022	Aug. 18, 2025
Stock Option Fifteen [Member]
Options Exercise Price	$ 6.4025	$ 6.8250
Options Outstanding (Shares)	261,789	8,791
Options Exercisable (Shares)	261,789	8,791
Options, Expiration Date	Aug. 18, 2025	Dec. 11, 2020
Stock Option Sixteen [Member]
Options Exercise Price	$ 6.8250	$ 7.3775
Options Outstanding (Shares)	8,791	523,077
Options Exercisable (Shares)	8,791	523,077
Options, Expiration Date	Dec. 11, 2020	Mar. 31, 2021
Stock Option Seventeen [Member]
Options Exercise Price	$ 7.3775	$ 8.1250
Options Outstanding (Shares)	523,077	169,231
Options Exercisable (Shares)	523,077	169,231
Options, Expiration Date	Mar. 31, 2021	Jun. 30, 2022
Stock Option Eighteen [Member]
Options Exercise Price	$ 8.1250	$ 13
Options Outstanding (Shares)	169,231	7,385
Options Exercisable (Shares)	169,231	7,385
Options, Expiration Date	Jun. 30, 2022	Mar. 13, 2019
Stock Option Nineteen [Member]
Options Exercise Price	$ 13.9750	$ 13
Options Outstanding (Shares)	3,385	3,846
Options Exercisable (Shares)	3,385	3,846
Options, Expiration Date	Mar. 14, 2024	Apr. 14, 2019
Stock Option Twenty [Member]
Options Exercise Price	$ 15.4700	$ 13.9750
Options Outstanding (Shares)	7,755	3,385
Options Exercisable (Shares)	7,755	3,385
Options, Expiration Date	Apr. 8, 2020	Mar. 14, 2024
Stock Option Twenty One [Member]
Options Exercise Price	$ 15.9250	$ 15.4700
Options Outstanding (Shares)	2,462	7,755
Options Exercisable (Shares)	2,462	7,755
Options, Expiration Date	Feb. 28, 2024	Apr. 8, 2020
Stock Option Twenty Two [Member]
Options Exercise Price	$ 16.6400	$ 15.9250
Options Outstanding (Shares)	1,538	2,462
Options Exercisable (Shares)	1,538	2,462
Options, Expiration Date	Jan. 29, 2020	Feb. 28, 2024
Stock Option Twenty Three [Member]
Options Exercise Price	$ 19.5000	$ 16.0500
Options Outstanding (Shares)	9,487	46,154
Options Exercisable (Shares)	9,487	46,154
Options, Expiration Date	Jul. 17, 2022	Jul. 17, 2019
Stock Option Twenty Four [Member]
Options Exercise Price	$ 19.5000	$ 16.6400
Options Outstanding (Shares)	6,410	1,538
Options Exercisable (Shares)	6,410	1,538
Options, Expiration Date	Aug. 10, 2022	Jan. 29, 2020
Stock Option Twenty Five [Member]
Options Exercise Price		$ 19.5000
Options Outstanding (Shares)		9,487
Options Exercisable (Shares)		9,487
Options, Expiration Date		Jul. 17, 2022
Stock Option Twenty Six [Member]
Options Exercise Price		$ 19.5000
Options Outstanding (Shares)		6,410
Options Exercisable (Shares)		6,410
Options, Expiration Date		Aug. 10, 2022

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	Jul. 21, 2016USD ($)	Jan. 12, 2016USD ($)	Jan. 12, 2016CAD ($)	Sep. 30, 2015USD ($)	Aug. 18, 2015USD ($)shares	Oct. 15, 2014USD ($)	Jun. 27, 2014USD ($)	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)shares	Jun. 30, 2018USD ($)	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)shares	Dec. 31, 2018USD ($)shares	Jan. 31, 2018USD ($)	Jan. 31, 2018CAD ($)	Dec. 31, 2017shares
Due and payable investment banking services	$ 225,000
Cash fee												$ 5,000
Stock options to purchase | shares								4,287,609	4,323,317		4,287,609	4,323,317	4,344,994			3,996,167
Principal cash obligations and commitments								$ 1,211,200			$ 1,211,200
Dr. Arnold S.Lippa [Member]
Cash compensation expense								84,900	$ 84,900		254,700	$ 254,700	$ 339,600
Stock options to purchase | shares					30,769
Health plan for employees expense					$ 1,200
Maximum health coverage amount per month					$ 1,000
Percentage of annual bonus from base salary					50.00%
Base salary					$ 300,000
Mr Margolis [Member]
Stock options to purchase | shares					30,769
Health plan for employees expense					$ 1,200
Maximum health coverage amount per month					1,000
Base salary					300,000
Dr. Manuso, Dr. Lippa, Mr. Margolis and Mr. Weingarten [Member]
Net proceeds from offering cost											2,000,000
Minimum [Member] | Mr Margolis [Member]
Bonuses					65,000
Maximum [Member] | Mr Margolis [Member]
Bonuses					$ 125,000
Consulting Agreement [Member] | DNA Healthlink, Inc [Member] | Richard Purcell [Member]
Cash fee						$ 12,500
Cash compensation expense								37,500	37,500		112,500	112,500
Employment Agreements [Member] | Tranche One [Member]
Cash bonuses				$ 15,000
Excess of financing cost				100,000
Employment Agreements [Member] | Tranche Two [Member]
Cash bonuses				15,000
Excess of financing cost				200,000
Employment Agreements [Member] | Tranche Three [Member]
Cash bonuses				30,000
Excess of financing cost				250,000
Employment Agreements [Member] | Jeff E. Margolis [Member]
Cash bonuses				60,000
Employment Agreements [Member] | Minimum [Member] | Jeff E. Margolis [Member]
Cash bonuses				$ 15,000
Recurring Cash Compensation Accrued Pursuant Amended Agreement [Member]
Cash compensation expense								80,400	80,400	$ 241,200	$ 241,200		$ 321,600
University of Illinois 2014 Exclusive License Agreement [Member]
License agreement effective date							Sep. 18, 2014
License fee							$ 25,000
Outstanding patent costs							$ 15,840
Percentage of royalty on net sale											4.00%
Percentage of payment on sub licensee revenue											12.50%
Minimum annual royalty payment amount											$ 100,000
Royalty due date											Feb. 28, 2019
Charge to operations with royalty obligation								$ 25,000	$ 25,000		$ 75,000	$ 75,000
University of Illinois 2014 Exclusive License Agreement [Member] | Research and Development Expenses [Member]
Minimum annual royalty payment amount											150,000
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After Dosing of First Patient Phase Three Human Clinical Trial [Member]
Payment for sale of product											350,000
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Five Days After First New Drug Application Filing [Member]
Payment for sale of product											500,000
University of Illinois 2014 Exclusive License Agreement [Member] | Due Within Twelve Months of First Commercial Sale Member [Member]
Payment for sale of product											1,000,000
University of Illinois 2014 Exclusive License Agreement [Member] | Maximum [Member] | First Sale Of Product [Member]
Minimum annual royalty payment amount											200,000
University of Illinois 2014 Exclusive License Agreement [Member] | Maximum [Member] | First Commercial Sale Of Product [Member]
Minimum annual royalty payment amount											$ 250,000
Neuroscience and Mental Health Institute at University of Alberta [Member]
Research grants award amount		$ 111,000
Additional cost budgeted under research grant		65,000
Funding cash installments		16,000
Payments to patent costs		15,000
Underwrite additional budgeted costs		$ 15,000
Accounts payable														$ 16,207
Foreign conversion exchange rate		0.76	0.76
Neuroscience and Mental Health Institute at University of Alberta [Member] | CAD [Member]
Research grants award amount			$ 146,000
Additional cost budgeted under research grant			85,000
Funding cash installments			21,000
Payments to patent costs			20,000
Underwrite additional budgeted costs			$ 20,000
Accounts payable															$ 21,222
Foreign conversion exchange rate		1	1

Commitments and Contingencies -

Commitments and Contingencies - Summary of Principal Cash Obligations and Commitments (Details)	Sep. 30, 2019USD ($)
2019	$ 315,300
2020	595,900
2021	100,000
2022	100,000
2023	100,000
Total	1,211,200
License Agreements [Member]
2019	25,000
2020	100,000
2021	100,000
2022	100,000
2023	100,000
Total	425,000
Litigation Settlement [Member]
2019	125,000
2020
2021
2022
2023
Total	125,000
Employment Agreements [Member]
2019	165,300	[1]
2020	495,900	[1]
2021		[1]
2022		[1]
2023		[1]
Total	$ 661,200	[1]
[1]	The payment of such amounts has been deferred indefinitely, as described above at "Employment Agreements." The 2019 amounts include three months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts renewed on September 30, 2018 and the 2019 obligations include the three months of obligations through December 31, 2019

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Nov. 12, 2019USD ($)$ / sharesshares	Nov. 04, 2019USD ($)TradingDaysshares	Oct. 28, 2019USD ($)$ / sharesshares	Oct. 22, 2019USD ($)TradingDays$ / sharesshares	Apr. 24, 2019USD ($)$ / sharesshares	Jun. 25, 2012	Sep. 30, 2019USD ($)shares	Dec. 31, 2018USD ($)	Sep. 30, 2018
Debt instrument interest rate									10.00%
Debt maturity date						Jun. 25, 2013
Debt instrument original issue discount							$ 104,858	$ 27,969
Number of shares reserved | shares							6,534,657
April 2019 Convertible Note [Member]
Debt instrument interest rate					10.00%
Debt maturity date					Apr. 24, 2020
Proceeds from convertible debt					$ 50,000
Debt face amount					$ 58,500
Debt instrument original issue discount							$ 27,211
Debt converted into shares | shares					147,541
Debt instrument, convertible, conversion price | $ / shares					$ 0.3964
Subsequent Event [Member] | October 2019 Convertible Note [Member]
Debt instrument interest rate				10.00%
Debt maturity date				Jul. 22, 2020
Proceeds from convertible debt				$ 54,500
Debt face amount				60,000
Debt instrument original issue discount				1,750
Capitalized note costs				$ 3,750
Number of restricted shares issued | shares				10,000
Warrant to purchase shares | shares				175,000
Warrant exercise price | $ / shares				$ 0.50
Warrant term				5 years
Debt instrument, consecutive trading days | TradingDays				20
Number of shares reserved | shares				1,935,000
Subsequent Event [Member] | November 2019 Convertible Note [Member]
Debt instrument interest rate		10.00%
Debt maturity date		Nov. 4, 2020
Proceeds from convertible debt		$ 147,900
Debt face amount		170,000
Debt instrument original issue discount		13,600
Capitalized note costs		$ 8,500
Warrant to purchase shares | shares
Debt instrument, description		The November 2019 Convertible Note may be prepaid subject to prepayment premium factors as described in the definitive documents and may not be prepaid after the 180th day. The holder may convert, at any time, the November 2019 Convertible Note at the holder's option into shares of the Company's common stock at a price that is 60% of the lowest trading price, taking into consideration only trades of 100 shares or more, for the twenty (20) consecutive trading days prior to and inclusive of the conversion date of such conversion.
Debt instrument, consecutive trading days | TradingDays		20
Number of shares reserved | shares		5,200,000
Subsequent Event [Member] | April 2019 Convertible Note [Member]
Debt converted into share, value	$ 10,000		$ 10,000
Debt converted into shares | shares	81,967		73,529
Debt instrument, convertible, conversion price | $ / shares	$ 0.1220		$ 0.1360
Convertible notes payable	$ 38,500